EP1141285A2 - Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure - Google Patents
Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäureInfo
- Publication number
- EP1141285A2 EP1141285A2 EP99962992A EP99962992A EP1141285A2 EP 1141285 A2 EP1141285 A2 EP 1141285A2 EP 99962992 A EP99962992 A EP 99962992A EP 99962992 A EP99962992 A EP 99962992A EP 1141285 A2 EP1141285 A2 EP 1141285A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- polypeptide
- pro
- sequence identity
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 574
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 565
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 560
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 283
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 176
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 176
- 238000000034 method Methods 0.000 claims abstract description 146
- 239000013598 vector Substances 0.000 claims abstract description 51
- 108020004414 DNA Proteins 0.000 claims description 312
- 210000004027 cell Anatomy 0.000 claims description 188
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 171
- 239000002773 nucleotide Substances 0.000 claims description 170
- 125000003729 nucleotide group Chemical group 0.000 claims description 170
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 104
- 239000002253 acid Substances 0.000 claims description 90
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 60
- 230000014509 gene expression Effects 0.000 claims description 51
- 108091026890 Coding region Proteins 0.000 claims description 38
- 108060003951 Immunoglobulin Proteins 0.000 claims description 33
- 102000018358 immunoglobulin Human genes 0.000 claims description 33
- 238000004113 cell culture Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 150
- 102000053602 DNA Human genes 0.000 description 128
- 102000004169 proteins and genes Human genes 0.000 description 92
- 230000000295 complement effect Effects 0.000 description 89
- 235000018102 proteins Nutrition 0.000 description 89
- 239000012634 fragment Substances 0.000 description 84
- 239000002299 complementary DNA Substances 0.000 description 78
- 125000000539 amino acid group Chemical group 0.000 description 74
- 238000012360 testing method Methods 0.000 description 68
- 239000005557 antagonist Substances 0.000 description 65
- 235000001014 amino acid Nutrition 0.000 description 62
- 241000282414 Homo sapiens Species 0.000 description 58
- 230000027455 binding Effects 0.000 description 57
- 239000000523 sample Substances 0.000 description 55
- 239000000556 agonist Substances 0.000 description 52
- 239000000203 mixture Substances 0.000 description 52
- 238000009396 hybridization Methods 0.000 description 46
- 229940024606 amino acid Drugs 0.000 description 40
- 150000001413 amino acids Chemical class 0.000 description 40
- 102000005962 receptors Human genes 0.000 description 38
- 108091034117 Oligonucleotide Proteins 0.000 description 37
- 108020003175 receptors Proteins 0.000 description 37
- 241001465754 Metazoa Species 0.000 description 35
- 241000124008 Mammalia Species 0.000 description 33
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 33
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 31
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 230000004071 biological effect Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 238000011282 treatment Methods 0.000 description 27
- 238000003556 assay Methods 0.000 description 26
- -1 survival factors Substances 0.000 description 24
- 239000011800 void material Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 21
- 230000001404 mediated effect Effects 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 21
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 20
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 20
- 230000003068 static effect Effects 0.000 description 20
- 108090000144 Human Proteins Proteins 0.000 description 19
- 102000003839 Human Proteins Human genes 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- 238000012216 screening Methods 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
- 230000000692 anti-sense effect Effects 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 238000004590 computer program Methods 0.000 description 18
- 230000028709 inflammatory response Effects 0.000 description 17
- 230000003993 interaction Effects 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 15
- 239000002502 liposome Substances 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 150000007513 acids Chemical group 0.000 description 14
- 229940127089 cytotoxic agent Drugs 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 239000003937 drug carrier Substances 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000000977 initiatory effect Effects 0.000 description 11
- 238000012544 monitoring process Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 240000007582 Corylus avellana Species 0.000 description 10
- 108091060211 Expressed sequence tag Proteins 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 230000013595 glycosylation Effects 0.000 description 10
- 238000006206 glycosylation reaction Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 239000013615 primer Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000002864 sequence alignment Methods 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000000074 antisense oligonucleotide Substances 0.000 description 9
- 238000012230 antisense oligonucleotides Methods 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 9
- 101150118300 cos gene Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 230000009261 transgenic effect Effects 0.000 description 9
- 239000004382 Amylase Substances 0.000 description 8
- 108010065511 Amylases Proteins 0.000 description 8
- 102000013142 Amylases Human genes 0.000 description 8
- 108020005544 Antisense RNA Proteins 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- 235000019418 amylase Nutrition 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000002254 cytotoxic agent Substances 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 101150075199 nei gene Proteins 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000003184 complementary RNA Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 229940124452 immunizing agent Drugs 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 238000007423 screening assay Methods 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 108020004491 Antisense DNA Proteins 0.000 description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108700023372 Glycosyltransferases Proteins 0.000 description 6
- 102000051366 Glycosyltransferases Human genes 0.000 description 6
- 108010064064 Junctional Adhesion Molecules Proteins 0.000 description 6
- 102000014748 Junctional Adhesion Molecules Human genes 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000009918 complex formation Effects 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000009459 hedgehog signaling Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 102000008983 Suppressor of fused Human genes 0.000 description 5
- 108050000968 Suppressor of fused Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000003816 antisense DNA Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000035160 transmembrane proteins Human genes 0.000 description 5
- 108091005703 transmembrane proteins Proteins 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 101100390711 Escherichia coli (strain K12) fhuA gene Proteins 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 4
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 3
- 101100407828 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ptr-3 gene Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 3
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 101150018266 degP gene Proteins 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 102000006029 inositol monophosphatase Human genes 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 108700003805 myo-inositol-1 (or 4)-monophosphatase Proteins 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000000059 patterning Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 101150059999 pro gene Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000010396 two-hybrid screening Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 206010062804 Basal cell naevus syndrome Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 244000060234 Gmelina philippensis Species 0.000 description 2
- 208000031995 Gorlin syndrome Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000979284 Homo sapiens Protein kinase C-binding protein NELL1 Proteins 0.000 description 2
- 101000995264 Homo sapiens Protein kinase C-binding protein NELL2 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 238000005588 Kraus reaction Methods 0.000 description 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229910009891 LiAc Inorganic materials 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 2
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 description 2
- 102100034433 Protein kinase C-binding protein NELL2 Human genes 0.000 description 2
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000311088 Schwanniomyces Species 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108091013841 Spermatogenesis-associated protein 6 Proteins 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100030859 Tissue factor Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 108010056243 alanylalanine Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000003458 notochord Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 101150093139 ompT gene Proteins 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 101150009573 phoA gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000008410 smoothened signaling pathway Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 101150108727 trpl gene Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- REIIOHUYMPSAPS-WVLIHFOGSA-N (ne)-n-[(1-methyl-2h-pyridin-6-yl)methylidene]hydroxylamine;hydrochloride Chemical compound Cl.CN1CC=CC=C1\C=N\O REIIOHUYMPSAPS-WVLIHFOGSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- PQYGLZAKNWQTCV-HNNXBMFYSA-N 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA Chemical compound OCCNC(=S)NC1=CC=C(C[C@@H](CN(CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 PQYGLZAKNWQTCV-HNNXBMFYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001504630 Alcedo Species 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 1
- RJUHZPRQRQLCFL-IMJSIDKUSA-N Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O RJUHZPRQRQLCFL-IMJSIDKUSA-N 0.000 description 1
- QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101710168454 Beta-galactosidase A Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000008523 COUP Transcription Factor II Human genes 0.000 description 1
- 108010020650 COUP Transcription Factor II Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 206010057648 Cyclopia Diseases 0.000 description 1
- 241001219085 Cyclopia Species 0.000 description 1
- 150000008448 D-mannosides Chemical class 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241001459693 Dipterocarpus zeylanicus Species 0.000 description 1
- 108700011583 Drosophila cos Proteins 0.000 description 1
- 108700032223 Drosophila fu Proteins 0.000 description 1
- 108700018846 Drosophila hh Proteins 0.000 description 1
- 101100229963 Drosophila melanogaster grau gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710202200 Endolysin A Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101000996823 Homo sapiens Cell surface A33 antigen Proteins 0.000 description 1
- 101000806149 Homo sapiens Dehydrogenase/reductase SDR family member 2, mitochondrial Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000701405 Homo sapiens Serine/threonine-protein kinase 36 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 101150000679 OPTN gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101710083394 Protein patched Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- OVSNDJXCFPSPDZ-UHFFFAOYSA-N Reactive red 120 Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=CC(NC=3N=C(NC=4C=CC(NC=5N=C(NC=6C7=C(O)C(N=NC=8C(=CC=CC=8)S(O)(=O)=O)=C(C=C7C=C(C=6)S(O)(=O)=O)S(O)(=O)=O)N=C(Cl)N=5)=CC=4)N=C(Cl)N=3)=C2C(O)=C1N=NC1=CC=CC=C1S(O)(=O)=O OVSNDJXCFPSPDZ-UHFFFAOYSA-N 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- AUEJLPRZGVVDNU-STQMWFEESA-N Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-STQMWFEESA-N 0.000 description 1
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ZYPGADGCNXOUJP-CXVPHVKISA-N Variotin Chemical compound CCCC[C@@H](O)\C=C(/C)\C=C\C=C\C(=O)N1CCCC1=O ZYPGADGCNXOUJP-CXVPHVKISA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 208000010927 atrophic thyroiditis Diseases 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 208000019748 bullous skin disease Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical class [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000002922 epistatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- HVCNNTAUBZIYCG-UHFFFAOYSA-N ethyl 2-[4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenoxy]propanoate Chemical compound C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=NC2=CC=C(Cl)C=C2S1 HVCNNTAUBZIYCG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000007192 granulomatous hepatitis Diseases 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 102000052519 human DHRS2 Human genes 0.000 description 1
- 102000054366 human GPA33 Human genes 0.000 description 1
- 102000053342 human STK36 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010667 large scale reaction Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 108010028826 multiple inositol-polyphosphate phosphatase Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000607 toxicokinetics Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Definitions
- the present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides.
- Extracellular proteins play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms.
- secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment.
- Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors.
- Most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins.
- Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents.
- Efforts are being undertaken by both industry and proficient to identify new, native secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Patent No. 5,536,637)].
- Membrane-bound proteins and receptors can play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms.
- membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesin molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins . Protein tyrosine kinases , enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.
- Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-hgand interactions
- Receptor immunoadhesins for instance, can be employed as therapeutic agents to block receptor-hgand interactions
- the membrane -bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/hgand interaction
- Hep27 protein is synthesized and accumulated in the nucleus of human hepatoblastoma cells (HepG2 cells) following growth arrest induced by butyrate treatment (Gabrielli et al , Eur J Biochem 232 473-477 (1995)) The synthesis of Hep27 is inhibited in cells that, released from the butyrate block, have resumed DNA synthesis
- the Hep27 protein sequence shows significant homology to the known short-chain alcohol dehydrogenase (SCAD) family of proteins and it has been suggested that Hep27 is a new member of the SCAD family of proteins In agreement with its nuclear localization, Hep27 has a region similar to the bipartite nuclear- targeting sequence and Hep27 mRNA expression and protein synthesis suggests the existence of a regulation at the post-transc ⁇ ptional level
- TGF- ⁇ transforming growth factor-beta
- Wnt fibroblast growth factors
- hedgehog families have been associated with patterning activity of different cells and structures in Drosophila as well as m vertebrates.
- Costal-2 is a novel kinesin-related protein in the Hedgehog signaling pathway Hedgehog (Hh) was first identified as a segment-polarity gene by a genetic screen in Drosophila melanogaster, Nusslem-Volhard et al , Roux. Arch. Dev.
- Hh also plays a role in the development of limbs (Krauss et al Cell 75 1431 44 (1993) Laufer et al Cell 79 993-1003 (1994)), somites (Fan and Tessier-Lavigne CeU 29, 1 175-86 (1994), Johnson et al , Cell 79 1165 73 (1994)), lungs (Bellusci et al , Develop J124 53-63 ( 1997) and sk (Oro et al , Science 276 817 21 (1997) Likewise, IHh and DHh are involved in bone, gut and germinal cell development, Apelqvist et al , Cttrr Biol 7 801-4 (1997), Bellusci et al , Dev Suppl Y2 ⁇
- the nei gene has been described to encode a protein that is expressed in the neural tissues of chicken (Watanabe et al. , Genomics 38(3):273-276 (1996)).
- NELL1 and NELL2 two novel human cDNAs (designated NELL1 and NELL2) have been isolated and characterized which encode polypeptides having homology to that encoded by the chicken nei gene, wherein those human polypeptides contain six EGF-like repeats (Watanabe et al. , supra). Given the neural-specific expression of these genes, it is suggested that they may play a role in neural development. There is, therefore, significant interest in identifying and characterizing novel polypeptides having homology to nei, NELL1 and NELL2.
- PRO 1434 polypeptides having homology to the nei protein, designated herein as PRO 1434 polypeptides.
- inositol phosphatases The characterization of inositol phosphatases is of interest because it is fundamental to the understanding of signaling activities that stimulate the release of Ca 2+ from the endoplasmic reticulum. Molecular cloning allowed the identification of a multiple inositol polyphosphate phosphatase which is highly expressed in kidney and liver (Craxton et al. (1997) Biochem J. 328:75-81).
- PRQ1868 The inflammatory response is complex and is mediated by a variety of signaling molecules produced locally by mast cells, nerve endings, platelets, leucocytes and complement activation. Certain of these signaling molecules cause the endothelial cell lining to become more porous and/or even to express selectins which act as cell surface molecules which recognize and attract leucocytes through specific carbohydrate recognition. Stronger leucocyte binding is mediated by integrins, which mediate leukocyte movement through the endothelium. Additional signaling molecules act as chemoattractants, causing the bound leucocytes to crawl towards the source of the attractant. Other signaling molecules produced in the course of an inflammatory response escape into the blood and stimulate the bone marrow to produce more leucocytes and release them into the blood stream
- Inflammation is typically initiated by an antigen, which can be virtually an> molecule capable of initiating an immune response Under normal physiological conditions these are foreign molecules, but molecules generated by the organism itself can serve as the catalyst as is known to occur in various disease states
- T-cell proliferation is a mixed lymphocyte culture or mixed lymphocyte reaction (MLR) is an established indication of the ability of a compound to stimulate the immune system
- MLR mixed lymphocyte reaction
- the responding leucocytes can be neutrophihc, eosinophihc, monocytic or lymphocytic Histological examination of the affected tissues provides evidence of an immune stimulating or inhibiting response
- IBD Inflammatory bowel disease
- IBD is a term used to collectively describe gut disorders including both ulcerative colitis (UC) and Crohn's disease, both of which are classified as distinct disorders, but share common features and likely share pathology
- IBD Inflammatory bowel disease
- IBD is a term used to collectively describe gut disorders including both ulcerative colitis (UC) and Crohn'
- JAM Junctional Adhesion Molecule
- the compounds of the invention also bear significant homology to A33 antigen, a known colorectal cancer-associated marker
- A33 antigen is expressed in more than 90% of primary or metastatic colon cancers as well as normal colon epithelium In carcinomas originating from the colonic mucosa, the A33 antigen is expressed homogeneously in more than 95 % of all cases
- the A33 antigen has not been detected m a wide range of other normal issues, I e its expression appears to be organ specific Therefore, the A33 antigen appears to play an important role in the induction of colorectal cancer
- mAbs monoclonal antibodies
- Radioactive gene, toxins and/or drug tagged mAbs can be used for treatment in situ with minimal patient description
- mAbs can also be used to diagnose during the diagnosis and treatment of colon cancers
- serum levels of the A33 antigen are elevated in a patient
- a drop of the levels after surgery would indicate the tumor resection was successful
- serum A33 antigen levels after surgery would indicate that metastases of the original tumor may have formed or that new primary tumors may have appeared
- monoclonal antibodies can be used in lieu of, or in conjunction with surgery and/or other chemotherapies
- preclimcal analysis and localization studies in patients infected with colorectal carcinoma with a mAb to A33 are described in Welt et al , J Chn Oncol 8 1894-1906 (19
- PRO 1868 polypeptides having homology to A33 antigen protein, designated herein as PRO 1868 polypeptides
- PR03434 polypeptides are novel secreted polypeptides.
- Proteins are glycosylated by a complex set of reactions which are mediated by membrane bound glycosyltransferases
- glycosyltransferases that account for the array of carbohydrate structures synthesized N-acetylglucosaminyltransferase proteins comprise a family of glycosyltransferases that provide for a variety of important biological functions in the mammalian organism
- UDP-N-acetylglucosamine alpha-3-D-mannos ⁇ de beta-l ,2-N-acetylglucosammyltransferase I is an glycosyltransferase that catalyzes an essential first step in the conversion of high-mannose N-glycans to hybrid and complex N-glycans (Sarkar et al , Proc Natl Acad Sci USA 88 234-238 (1991) UPD-N- acetylglucosamine alpha 1 3 D-mannoside
- a cDNA clone (DN A35672-2508) has been identified, having homology to nucleic acid encoding Hep27 protem, that encodes a novel polypeptide, designated m the present application as "PRO1800"
- the mvention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1800 polypeptide
- the invention concerns an isolated nucleic acid molecule encoding a PRO1800 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 36 or about 81 and about 869, inclusive, of Figure 1 (SEQ ID NO 1)
- hybridization occurs under stringent hybridization and wash conditions
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203538 (DNA35672-2508) or (b) the complement of the nucleic acid molecule of (a)
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203538 (DNA35672-2508)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 16 to about 278, inclusive of Figure 2 (SEQ ID NO 2), or (b) the complement of the DNA of (a)
- the invention concerns an isolated nucleic acid molecule having at least 230 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO1800 polypeptide having the sequence of ammo acid residues from 1 or about 16 to about 278, inclusive of Figure 2 (SEQ ID NO 2), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA molecule.
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1800 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine,or is complementary to such encoding nucleic acid molecule.
- the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 15 in the sequence of Figure 2 (SEQ ID NO: 1
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85 % positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 16 to about 278, inclusive of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA of (a).
- nucleic acid fragments may be from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 1 (SEQ ID NO: l).
- the invention provides isolated PRO 1800 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
- the invention provides isolated native sequence PRO1800 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 16 to about 278 of Figure 2 (SEQ ID NO:2).
- the invention concerns an isolated PRO 1800 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 16 to about 278, inclusive of Figure 2 (SEQ ID NO:2).
- the invention concerns an isolated PRO 1800 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85 % positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 16 to about 278, inclusive of Figure 2 (SEQ ID NO:2).
- the invention concerns an isolated PRO1800 polypeptide, comprising the sequence of amino acid residues 1 or about 16 to about 278, inclusive of Figure 2 (SEQ ID NO:2), or a fragment thereof sufficient to provide a binding site for an anti-PRO1800 antibody.
- the PRO 1800 fragment retains a qualitative biological activity of a native PRO 1800 polypeptide.
- the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1800 polypeptide having the sequence of amino acid residues from about 1 or about 16 to about 278, inclusive of Figure 2 (SEQ ID NO: 3), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferabl ⁇ at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (n) cultu ⁇ ng a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture
- the invention concerns agonists and antagonists of a native PRO 1800 polypeptide
- the agonist or antagonist is an anti PRO 1800 antibody
- the invention concerns a method of identifying agonists or antagonists of a native PRO 1800 polypeptide by contacting the native PRO 1800 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide
- the mvention concerns a composition comprising a PRO 1800 polypeptide, or an agonist or antagonist as hereinabove defined in combination with a pharmaceutically acceptable carrier
- a cDNA clone (DNA47465-1561) has been identified, having homology to nucleic acid encoding Costal-2 protein, that encodes a novel polypeptide, designated in the present application as 'PR0539"
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0539 polypeptide
- the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR0539 polypeptide having the sequence of ammo acid residues from about 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7), or (b) the complement of the DNA molecule of (a)
- the invention concerns an isolated nucleic acid molecule encoding a PR0539 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 186 and about 2675, inclusive, of Figure 3 (SEQ ID NO 6)
- hybridization occurs under stringent hybridization and wash conditions
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203661 (DNA47465-1561) or (b) the complement of the nucleic acid molecule of (a)
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203661 (DNA47465-1561)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7), or (b) the complement of the DNA of (a)
- the invention concerns an isolated nucleic acid molecule having at least 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR0539 polypeptide having the sequence of ammo acid residues from 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0539 polypeptide, with or without the initiating methiomne, or is complementary to such encoding nucleic acid molecule
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7), or (b) the complement of the DNA of (a) Another embodiment is directed to fragments of a PR0539 polypeptide coding sequence that may find use as hybridization probes Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from
- the invention provides isolated native sequence PR0539 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 to about 830 of Figure 4 (SEQ ID NO 7)
- the invention concerns an isolated PR0539 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of amino acid residues 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7)
- the invention concerns an isolated PR0539 polypeptide, comprising an ammo acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7)
- the invention concerns an isolated PR0539 polypeptide, comprising the sequence of amino acid residues 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7), or a fragment thereof sufficient to provide a binding site for an ant ⁇ -PR0539 antibody
- the PR0539 fragment retains a qualitative biological activity of a native PR0539 polypeptide
- the invention provides a polypeptide produced by (1) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR0539 polypeptide having the sequence of amino acid residues from about 1 to about 830, inclusive of Figure 4 (SEQ ID NO 7), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), ( ⁇ ) culturmg a
- the invention concerns agonists and antagonists of a native PR0539 polypeptide
- the agonist or antagonist is an anti PR0539 antibody
- the invention concerns a method of identifying agonists or antagonists of a native PR0539 polypeptide by contacting the native PR0539 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide
- the biological activity is either binding to microtubiles or the ability to complex with fused and cubitus mterruptus
- the invention concerns a composition
- a composition comprising a PR0539 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier
- the invention provides for compounds and methods for developing antagonists against and agonist promoting PR0539 modulation of Hedgehog signaling
- an antagonist of vertebrate PR0539 which blocks, prevents, inhibits and/or neutralized the normal functioning of PR0539 in SH signaling pathway, including both small bioorgamc molecules and antisense nucleotides
- the invention provides for alternatively spliced variants of human PR0539
- the invention provides a method of screening or assaying for identifying molecules that alter the PR0539 modulation of hedgehog signaling
- the molecules either prevent interaction of PR0539 with its associative complexmg proteins (such as fused or cubitus mterruptus) or prevent or inhibit dissociation of complexes
- the assay comprises the incubation of a mixture comprising PR0539 and a substrate with a candidate molecule and detection of the ability of the candidate molecule to modulate PR0539 hedgehog signaling
- the screened molecules preferably are small molecule drug candidates
- the method relates to a technique of diagnosing to determine whether a particular disorder is modulated by hedgehog signaling, comprising
- a cDNA clone (DNA57700-1408) has been identified that encodes a novel polypeptide, designated in the present application as "PR0982
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0982 polypeptide
- the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR0982 polypeptide having the sequence of amino acid residues from 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO 9), or
- the invention concerns an isolated nucleic acid molecule encoding a PR0982 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 89 and about 400, inclusive, of Figure 5 (SEQ ID NO 8)
- hybridization occurs under stringent hybridization and wash conditions
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA m ATCC Deposit No 203583 (DNA57700-1408), or (b) the complement of the DNA molecule of (a)
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203583 (DNA57700-1408)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO: 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO:
- the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR0982 polypeptide having the sequence of amino acid residues from 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO 9), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0982 polypeptide, with or without the N-terminal signal sequence and/or the initiating methiomne, or is complementary to such encoding nucleic acid molecule
- the signal peptide has been tentatively identified as extending from ammo acid position 1 through about amino acid position 21 m the sequence of Figure 6 (SEQ ID NO-9)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the ammo acid sequence of residues 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO 9), or (b) the complement of the DNA of (a)
- nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides m length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length
- the invention provides isolated PR0982 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined
- the invention provides isolated native sequence PR0982 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 or about 22 to 125 of Figure 6 (SEQ ID NO 9)
- the invention concerns an isolated PR0982 polypeptide, comprising an ammo acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of amino acid residues 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO 9)
- the invention concerns an isolated PR0982 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 22 to 125 of Figure 6 (SEQ ID NO 9)
- the invention concerns an isolated PR0982 polypeptide, comprising the sequence of amino acid residues 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO 9), or a fragment thereof sufficient to provide a binding site for an ant ⁇ -PR0982 antibody
- the PR0982 fragment retains a qualitative biological activity of a native PR0982 polypeptide
- the invention provides a polypeptide produced by (l) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR0982 polypeptide having the sequence of amino acid residues from 1 or about 22 to about 125, inclusive of Figure 6 (SEQ ID NO 9), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (u) culturmg a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture
- a cDNA clone (DNA68818-2536) has been identified, having homology to nucleic acid encoding nei protein, that encodes a novel polypeptide, designated in the present application as "PR01434"
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1434 polypeptide
- the isolated nucleic acid comprises DNA having at least about 80% sequence identity preferably at least about 85 % sequence identi more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1434 polypeptide having the sequence of ammo acid residues from about 1 or about 28 to about 325, inclusive of Figure 8 (SEQ ID NO 11), or (b) the complement of the DNA molecule of (a)
- the invention concerns an isolated nucleic acid molecule encoding a PR01434 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 581 or about 662 and about 1555, inclusive, of Figure 7 (SEQ ID NO 10) Preferably, hybridization occurs under stringent hybridization and wash conditions
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferabl) at least about 95 % sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protem cDNA in ATCC Deposit No 203657 (DNA68818-2536) or (b) the complement of the nucleic acid molecule of (a)
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203657 (DNA68818-2536)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of ammo acid residues 1 or about 28 to about 325, inclusive of Figure 8 (SEQ ID NO 11), or (b) the complement of the DNA of (a)
- the invention concerns an isolated nucleic acid molecule having at least 65 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1434 polypeptide having the sequence of amino acid residues from 1 or about 28 to about 325, inclusive of Figure 8 (SEQ ID NO 11), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, prefereably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule
- the invention provides an isolated nucleic acid molecule comprising DNA encodmg a PR01434 polypeptide, with or without the N-terminal signal sequence and/or the initiating methiomne, and its soluble, I e , transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule
- the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 27 in the sequence of Figure 8 (SEQ ID NO 11)
- the transmembrane domain has been tentatively identified as extending from about amino acid position 11 to about amino acid position 30 in the PR01434 amino acid sequence ( Figure 8, SEQ ID NO 11)
- the mvention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the
- nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 7 (SEQ ID NO: 10).
- the invention provides isolated PR01434 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
- the invention provides isolated native sequence PR01434 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 28 to about 325 of Figure 8 (SEQ ID NO: 11).
- the invention concerns an isolated PRO 1434 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of amino acid residues 1 or about 28 to about 325, inclusive of Figure 8 (SEQ ID NO: 11).
- the invention concerns an isolated PRO 1434 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 28 to about 325, inclusive of Figure 8 (SEQ ID NO: 11).
- the invention concerns an isolated PRO 1434 polypeptide, comprising the sequence of amino acid residues 1 or about 28 to about 325, inclusive of Figure 8 (SEQ ID NO: 11), or a fragment thereof sufficient to provide a binding site for an anti-PR01434 antibody.
- the PR01434 fragment retains a qualitative biological activity of a native PRO 1434 polypeptide.
- the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1434 polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 325, inclusive of Figure 8 (SEQ ID NO: 11), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- the invention concerns agonists and antagonists of a native PRO 1434 polypeptide.
- the agonist or antagonist is an anti-PR01434 antibody.
- the invention concerns a method of identifying agonists or antagonists of a native PR01434 polypeptide by contacting the native PR01434 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
- the invention concerns a composition
- a composition comprising a PR01434 polypeptide, or an agonist or antagonist as hereinabove defined in combination with a pharmaceutically acceptable carrier
- a cDNA clone (DNA59847-2510) has been identified that encodes a novel transmembrane polypeptide, designated in the present application as "PRO 1863
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1863 polypeptide
- the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1863 polypeptide having the sequence of amino acid residues from about 1 or about 16 to about 437, inclusive of Figure 10 (SEQ ID NO: 1)
- the invention concerns an isolated nucleic acid molecule encoding a PRO 1863 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 17 or about 62 and about 1327, inclusive, of Figure 9 (SEQ ID NO 15) Preferably, hybridization occurs under stringent hybridization and wash conditions
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203576 (DNA59847-2510) or (b) the complement of the nucleic acid molecule of (a)
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203576 (DNA59847 2510)
- the invention concerns an isolated nucleic acid molecule having at least 345 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1863 polypeptide having the sequence of amino acid residues from 1 or about 16 to about 437, inclusive of Figure 10 (SEQ ID NO 16), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1863 polypeptide, with or without the N-terminal signal sequence and/or the initiating methiomne, and its soluble, I e , transmembrane domain deleted or inactivated variants
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85 % positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 16 to about 437, inclusive of Figure 10 (SEQ ID NO 16), or (b) the complement of the DNA of (a)
- nucleic acid fragments are from about 20 to about 80 nucleotides m length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown m Figure 9 (SEQ ID NO 15)
- the invention provides isolated PRO 1863 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified
- the invention provides isolated native sequence PRO 1863 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 16 to about 437 of Figure 10 (SEQ ID NO 16)
- the invention concerns an isolated PRO 1863 polypeptide, comprising an ammo acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of ammo acid residues 1 or about 16 to about 437, inclusive of Figure 10 (SEQ ID NO 16)
- the invention concerns an isolated PRO 1863 polypeptide, comprising an ammo acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 16 to about 437, inclusive of Figure 10 (SEQ ID NO 16)
- the invention concerns an isolated PR01863 polypeptide, comprising the sequence of ammo acid residues 1 or about 16 to about 437, inclusive of Figure 10 (SEQ ID NO 16), or a fragment thereof sufficient to provide a binding site for an ant ⁇ -PR01863 antibody
- the PRO 1863 fragment retains a qualitative biological activity of a native PRO 1863 polypeptide
- the invention provides a polypeptide produced by (l) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1863 polypeptide having the sequence of ammo acid residues from about 1 or about 16 to about 437, inclusive of Figure 10 (SEQ ID NO 16), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), ( ⁇ ) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture.
- the invention concerns agonists and antagonists of a native PRO 1863 polypeptide.
- the agonist or antagonist is an anti-PR01863 antibody.
- the invention concerns a method of identifying agonists or antagonists of a native PRO 1863 polypeptide by contacting the native PRO 1863 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
- the invention concerns a composition
- a composition comprising a PRO 1863 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
- PRQ1917 A cDNA clone (DNA76400-2528) has been identified that encodes a novel polypeptide having homology to inositol phosphatase and designated in the present application as "PR01917” .
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01917 polypeptide.
- the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1917 polypeptide having the sequence of amino acid residues from 1 or about 31 to about 487, inclusive of Figure 12 (SEQ ID NO: 18), or (b) the complement of the DNA molecule of (a).
- the invention concerns an isolated nucleic acid molecule encoding a PR01917 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 96 and about 1466, inclusive, of Figure 11 (SEQ ID NO: 17).
- hybridization occurs under stringent hybridization and wash conditions.
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203573 (DNA76400-2528), or (b) the complement of the DNA molecule of (a).
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203573 (DNA76400-2528).
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from 1 or about 31 to about 487, inclusive of Figure 12 (SEQ ID NO: 18), or the complement of the DNA of (a).
- the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1917 polypeptide having the sequence of amino acid residues from 1 or about 31 to about 487, inclusive of Figure 12 (SEQ ID NO: 18), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA molecule.
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01917 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule.
- the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 30 in the sequence of Figure 12 (SEQ ID NO: 1
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 31 to about 487, inclusive of Figure 12 (SEQ ID NO: 18), or (b) the complement of the DNA of (a).
- nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
- the invention provides isolated PR01917 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
- the invention provides isolated native sequence PR01917 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 or about 31 to 487 of Figure 12 (SEQ ID NO: 18).
- the invention concerns an isolated PRO 1917 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 31 to about 487, inclusive of Figure 12 (SEQ ID NO: 18).
- the invention concerns an isolated PR01917 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 31 to 487 of Figure 12 (SEQ ID NO: 18).
- the invention concerns an isolated PRO 1917 polypeptide, comprising the sequence of amino acid residues 1 or about 31 to about 487, inclusive of Figure 12 (SEQ ID NO: 18), or a fragment thereof sufficient to provide a binding site for an anti-PR01917 antibody.
- the PRO 1917 fragment retains a qualitative biological activity of a native PRO 1917 polypeptide.
- the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1917 polypeptide having the sequence of amino acid residues from 1 or about 31 to about 487, inclusive of Figure 12 (SEQ ID NO: 18), or (b) the complement of the DNA molecule of (a) and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), ( ⁇ ) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture
- the invention concerns agonists and antagonists of a native PR01917 polypeptide
- the agonist or antagonist is an anti PRO 1917 antibody
- the invention concerns a method of identifying agonists or antagonists of a native PRO 1917 polypeptide, by contacting the native PRO 1917 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide
- the invention concerns a composition comprising a PRO 1917 polypeptide, or an agonist or antagonist as hereinabove defined, m combination with a pharmaceutically acceptable carrier
- the present invention concerns compositions and methods for the diagnosis and treatment of inflammatory diseases in mammals, including humans
- the present invention is based on the identification of proteins (including agonist and antagonist antibodies) which either stimulate or inhibit the immune response m mammals
- Inflammatory diseases can be treated by suppressing the inflammatory response Molecules that enhance an inflammatory response stimulate or potentiate the immune response to an antigen Molecules which stimulate an inflammatory response can be inhibited where suppression of the inflammatory response would be beneficial Molecules which stimulate the inflammatory response can be used therapeutically where enhancement of the inflammatory response would be beneficial
- Such stimulatory molecules can also be inhibited where suppression of the inflammatory response would be of value
- Neutralizing antibodies are examples of molecules that inhibit molecules having immune stimulatory activity and which would be beneficial in the treatment of inflammatory diseases Molecules which inhibit the inflammatory response can also be utilized (proteins directly or via the use of antibody agonists) to inhibit the inflammatory response and thus ameliorate inflammatory diseases
- the proteins of the invention are useful for the diagnosis and/or treatment (including prevention) of immune related diseases
- Antibodies which bind to stimulatory proteins are useful to suppress the inflammatory response
- Antibodies which bind to inhibitory proteins are useful to stimulate inflammatory response and the immune system
- the proteins and antibodies of the invention are also useful to prepare medicines and medicaments for the treatment of inflammatory and immune related diseases
- the invention concerns antagonists and agonists of a PRO 1868 polypeptide that inhibits one or more of the functions or activities of a PRO 1868 polypeptide
- the invention concerns a method for determining the presence of a PRO 1868 polypeptide comprising exposing a cell suspected of containing the polypeptide to an anti-PRO 1868 antibody and determining binding of the antibody to the cell
- the present invention relates to a method of diagnosing an inflammatory related disease in a mammal, comprising detecting the level of expression of a gene encoding a PRO 1868 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher expression level in the test sample indicates the presence of an inflammatory disease in the mammal.
- the present invention relates to method of diagnosing an inflammatory disease in a mammal, comprising (a) contacting an anti-PRO 1868 antibody with a test sample of tissue culture cells obtained from the mammal, and (b) detecting the formation of a complex between the antibody and the PRO 1868 polypeptide.
- the detection may be qualitative or quantitative, and may be performed in comparison with monitoring the complex formation in a control sample of known normal tissue cells of the same cell type. A larger quantity of complexes formed in the test sample indicates the presence of tumor in the mammal from which the test tissue cells were obtained.
- the antibody preferably carries a detectable label. Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art.
- the test sample is usually obtained from an individual suspected of having a deficiency or abnormality relating to the inflammatory response.
- the present invention relates to a diagnostic kit, containing an anti-PRO 1868 antibody and a carrier (e.g., a buffer) in suitable packaging.
- a carrier e.g., a buffer
- the kit preferably contains instructions for using the antibody to detect the PRO 1868 polypeptide.
- the invention concerns an article of manufacture, comprising: a container; a label on the container; and a composition comprising an active agent contained within the container; wherein the composition is effective for stimulating or inhibiting an inflammatory response in a mammal, the label on the container indicates that the composition can be used to treat an inflammatory disease, and the active agent in the composition is an agent stimulating or inhibiting the expression and/or activity of the PRO 1868 polypeptide .
- the active agent is a PRO 1868 polypeptide or an anti-PRO 1868 antibody.
- a further embodiment is a method for identifying a compound capable of inhibiting the expression and/or activity of a PRO 1868 polypeptide by contacting a candidate compound with a PRO 1868 polypeptide under conditions and for time sufficient to allow these two compounds to interact.
- either the candidate compound or the PRO 1868 polypeptide is immobilized on a solid support.
- the non-immobilized component carries a detectable label.
- the invention relates to a method of treating an inflammatory disease, by administration of an effective therapeutic amount of a PRO 1868 antagonist to a patient in need thereof for the treatment of a disease selected from: inflammatory bowel disease, systemic lupus erythematosis, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's syndrome, systemic vaculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis),
- a disease selected
- the invention provides a method for inhibiting the growth of tumor cells comprising exposing a cell which overexpresses a PRO 1868 polypeptide to an effective amount of an agent inhibiting the expression and/or activity of the PRO 1868 polypeptide
- the agent preferably is an anti PRO 1868 polypeptide, a small organic and inorganic peptide, phosphopeptide, antisense or ribozyme molecule, or a triple helix molecule
- the agent, e g , anti-PRO 1868 antibody induces cell death
- the tumor cells are further exposed to radiation treatment and/or a cytotoxic or chemotherapeutic agent
- the invention concerns an article of manufacture, comprising a container, a label on the container, and a composition comprising an active agent contained within the contamer, wherein the composition is effective for inhibiting the growth of tumor cells, the label on the container indicates that the composition can be used for treating conditions characterized by overexpression of a PRO 1868 poly
- a cDNA clone (DNA77624-2515) has been identified, having homology to nucleic acid encoding A33 antigen, that encodes a novel polypeptide, designated in the present application as "PRO 1868"
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1868 polypeptide
- the invention concerns an isolated nucleic acid molecule encoding a PRO 1868 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 51 or about 141 and about 980, inclusive, of Figure 13 (SEQ ID NO 19) Preferably, hybridization occurs under stringent hybridization and wash conditions
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203553 (DNA77624-2515) or (b) the complement of the nucleic acid molecule of (a)
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203553 (DNA77624-2515)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 31 to about 310 inclusive of Figure 14 (SEQ ID NO: 1
- the invention concerns an isolated nucleic acid molecule having at least 390 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1868 polypeptide having the sequence of amino acid residues from 1 or about 31 to about 310, inclusive of Figure 14 (SEQ ID NO 20), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA molecule
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1868 polypeptide, with or without the N-terminal signal sequence and/or the initiating methiomne, and its soluble, 1 e , transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule
- the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 30 in the sequence of Figure 14 (SEQ ID NO 20)
- the transmembrane domain has been tentatively identified as extending from about amino acid position 243 to about amino acid position 263 in the PR01868 amino acid sequence ( Figure 14, SEQ ID NO 20)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of
- the invention provides isolated native sequence PRO 1868 polypeptide, which in certain embodiments, includes an ammo acid sequence comprising residues 1 or about 31 to about 310 of Figure 14 (SEQ ID NO 20)
- the invention concerns an isolated PRO 1868 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 31 to about 310, inclusive of Figure 14 (SEQ ID NO 20)
- the invention concerns an isolated PRO 1868 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the ammo acid sequence of residues 1 or about 31 to about 310, inclusive of Figure 14 (SEQ ID NO 20)
- the invention concerns an isolated PRO 1868 polypeptide, comprising the sequence of amino acid residues 1 or about 31 to about 310, inclusive of Figure 14 (SEQ ID NO 20), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1868 antibody
- the PRO 1868 fragment retains a qualitative biological activity of a native PRO 1868 polypeptide
- the mvention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1868 polypeptide having the sequence of amino acid residues from about 1 or about 31 to about 310, inclusive of Figure 14 (SEQ ID NO 20), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (n) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- the invention concerns agonists and antagonists of a native PRO 1868 polypeptide.
- the agonist or antagonist is an anti-PR01868 antibody.
- the invention concerns a method of identifying agonists or antagonists of a native PRO 1868 polypeptide by contacting the native PRO 1868 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
- the invention concerns a composition
- a composition comprising a PRO 1868 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
- the invention provides a composition containing a PRO 1868 polypeptide or an agonist or antagonist antibody in admixture with a carrier or excipient.
- the composition contains a therapeutically affective amount of the peptide or antibody.
- the composition when the composition contains an inflammation stimulating molecule, the composition is useful for: (a) increasing infiltration of inflammatory cells into a tissue of a mammal in need thereof, (b) stimulating or enhancing an immune response in a mammal in need thereof, or (c) increasing the proliferation of T-lymphocytes in a mammal in need thereof in response to an antigen.
- the composition when the composition contains an inflammatory inhibiting molecule, the composition is useful for: (a) decreasing infiltration of inflammatory cells into a tissue of a mammal in need thereof, (b) inhibiting or reducing an inflammatory response in a mammal in need thereof, or (c) decreasing the proliferation of T-lymphocytes in a mammal in need thereof in response to an antigen.
- the composition contains a further active ingredient, which may, for example, be a further antibody or a cytotoxic or chemotherapeutic agent.
- the composition is sterile.
- the invention concerns nucleic acid encoding an anti-PRO 1868 antibody, and vectors and recombinant host cells comprising such nucleic acid.
- the invention concerns a method for producing such an antibody by culturing a host cell transformed with nucleic acid encoding the antibody under conditions such that the antibody is expressed, and recovering the antibody from the cell culture.
- a cDNA clone (DNA77631-2537) has been identified that encodes a novel polypeptide, designated in the present application as "PR03434. "
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR03434 polypeptide.
- the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR03434 polypeptide having the sequence of amino acid residues from 1 or about 17 to about 1029, inclusive of Figure 16 (SEQ ID NO:22), or (b) the complement of the DNA molecule of (a).
- the invention concerns an isolated nucleic acid molecule encoding a PR03434 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 46 or about 94 and about 3132, inclusive, of Figure 15 (SEQ ID NO 21)
- hybridization occurs under stringent hybridization and wash conditions
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203651 (DNA77631-2537), or (b) the complement of the DNA molecule of (a)
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203651 (DNA77631-2537)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of ammo acid residues from 1 or about 17 to
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR03434 polypeptide, with or without the N terminal signal sequence and/or the initiating methiomne, or is complementary to such encoding nucleic acid molecule
- the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 16 in the sequence of Figure 16 (SEQ ID NO 22)
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 17 to about 1029, inclusive of Figure 16 (SEQ ID NO 22), or (b) the complement of the DNA of (a)
- nucleic acid fragments are from about 20 to about 80 nucleotides m length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides m length
- the mvention provides isolated PR03434 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined
- the invention provides isolated native sequence PR03434 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 or about 17 to 1029 of Figure 16 (SEQ ID NO:22).
- the invention concerns an isolated PR03434 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 17 to about 1029, inclusive of Figure 16 (SEQ ID NO:22).
- the invention concerns an isolated PR03434 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 17 to 1029 of Figure 16 (SEQ ID NO:22).
- the invention concerns an isolated PR03434 polypeptide, comprising the sequence of amino acid residues 1 or about 17 to about 1029, inclusive of Figure 16 (SEQ ID NO:22), or a fragment thereof sufficient to provide a binding site for an anti-PR03434tibody .
- the PR0982 fragment retains a qualitative biological activity of a native PR03434 polypeptide.
- the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR03434 polypeptide having the sequence of amino acid residues from 1 or about 17 to about 1029, inclusive of Figure 16 (SEQ ID NO:22), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- the invention concerns agonists and antagonists of a native PR03434 polypeptide.
- the agonist or antagonist is an anti-PR03434 antibody.
- the invention concerns a method of identifying agonists or antagonists of a native PR03434 polypeptide, by contacting the native PR03434 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
- the invention concerns a composition
- a composition comprising a PR03434 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
- a cDNA clone (DNA82307-2531 )has been identified that encodes a novel polypeptide having homology to glycosyltransferases, and is designated in the present application as "PR01927”.
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1927 polypeptide .
- the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1927 polypeptide having the sequence of amino acid residues from 1 or about 24 to about 548, inclusive of Figure 18 (SEQ ID NO:24), or (b) the complement of the DNA molecule of (a).
- the invention concerns an isolated nucleic acid molecule encoding a PR01927 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 120 and about 1694, inclusive, of Figure 17 (SEQ ID NO:23).
- hybridization occurs under stringent hybridization and wash conditions.
- the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203537 (DNA82307-2531), or (b) the complement of the DNA molecule of (a).
- the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203537 (DNA82307-2531).
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from 1 or about 24 to about 548, inclusive of Figure 18 (SEQ ID NO:24), or the complement of the DNA of (a).
- the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1927 polypeptide having the sequence of amino acid residues from 1 or about 24 to about 548, inclusive of Figure 18 (SEQ ID NO:24), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
- the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1927 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. transmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule.
- the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 23 in the sequence of Figure 18 (SEQ ID NO:24).
- a type II transmembrane domain has been tentatively identified as extending from about amino acid position 6 to about amino acid position 25 in the PR01927 amino acid sequence ( Figure 18, SEQ ID NO:24).
- the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 24 to about 548, inclusive of Figure 18 (SEQ ID NO:24), or (b) the complement of the DNA of (a).
- Another embodiment is directed to fragments of a PRO 1927 polypeptide coding sequence that may find use as hybridization probes.
- nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
- the invention provides isolated PRO 1927 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
- the invention provides isolated native sequence PRO 1927 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 or about 24 to 548 of Figure 18 (SEQ ID NO:24).
- the invention concerns an isolated PRO 1927 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 24 to about 548, inclusive of Figure 18 (SEQ ID NO:24).
- the invention concerns an isolated PR01927 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85 % positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 24 to 548 of Figure 18 (SEQ ID NO:24).
- the invention concerns an isolated PRO 1927 polypeptide, comprising the sequence of amino acid residues 1 or about 24 to about 548, inclusive of Figure 18 (SEQ ID NO:24), or a fragment thereof sufficient to provide a binding site for an anti-PR01927 antibody.
- the PR01927 fragment retains a qualitative biological activity of a native PRO 1927 polypeptide.
- the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1927 polypeptide having the sequence of amino acid residues from 1 or about 24 to about 548, inclusive of Figure 18 (SEQ ID NO:24), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- the invention concerns agonists and antagonists of a native PRO 1927 polypeptide.
- the agonist or antagonist is an anti-PR01927 antibody.
- the invention concerns a method of identifying agonists or antagonists of a native PRO 1927 polypeptide, by contacting the native PRO 1927 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
- the invention concerns a composition comprising a PRO 1927 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier 10.
- the invention provides vectors comprising DNA encoding any of the herein described polypeptides
- Host cell comprising any such vector are also provided
- the host cells may be CHO cells, E coli, or yeast
- a process for producing any of the herein described polypeptides is further provided and comprises culturmg host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture
- the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence
- Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin
- the invention provides an antibody which specifically binds to any of the above or below described polypeptides
- the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody
- the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences
- the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide
- the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least at least
- the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97 % sequence identity, yet more preferably at least about 98% sequence identity and yet more
- the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95 % sequence identity , yet more preferably at least about 96 % sequence identity , yet more preferably at least about 97% sequence identity, yet more preferably at least about
- Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain- inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.
- Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes.
- nucleic acid fragments are usually at least about 20 nucleotides in length, preferably at least about 30 nucleotides in length, more preferably at least about 40 nucleotides in length, yet more preferably at least about 50 nucleotides in length, yet more preferably at least about 60 nucleotides in length, yet more preferably at least about 70 nucleotides in length, yet more preferably at least about 80 nucleotides in length, yet more preferably at least about 90 nucleotides m length yet more preferably at least about 100 nucleotides in length, yet more preferably at least about 1 10 nucleotides in length, yet more preferably at least about 120 nucleotides in length, yet more preferably at least about 130 nucleotides in length, yet more preferably at least about 140 nucleotides in length yet more preferably at least about 150 nucleotides m length, yet more preferably at least about 160 nucleotides m length, yet more preferably at least about 170 nucle
- the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified
- the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least about
- the invention concerns an isolated PRO polypeptide comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 81 % positives, more preferably at least about 82% positives, yet more preferably at least about 83 % positives, yet more preferably at least about 84% positives, yet more preferably at least about 85 % positives, yet more preferably at least about 86% positives, yet more preferably at least about 87% positives, yet more preferably at least about 88% positives, yet more preferably at least about 89% positives, yet more preferably at least about 90% positives, yet more preferably at least about 91 % positives, yet more preferably at least about 92% positives, yet more preferably at least about 93% positives, yet more preferably at least about 94% positives, yet more preferably at least about 95% positives, yet more preferably at least about 96% positives, yet more preferably at least about 97% positives, yet more preferably at least about 98% positives and yet more preferably at least at least
- the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described.
- Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.
- the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.
- the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein.
- the agonist or antagonist is an anti-PRO antibody or a small molecule.
- the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide.
- the PRO polypeptide is a native PRO polypeptide.
- the invention concerns a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier.
- the carrier is a pharmaceutically acceptable carrier.
- Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.
- Figure 1 shows a nucleotide sequence (SEQ ID NO: 1) of a native sequence PRO1800 cDNA, wherein SEQ ID NO: l is a clone designated herein as "DNA35672-2508".
- Figure 2 shows the amino acid sequence (SEQ ID NO: 2) derived from the coding sequence of SEQ ID NO: l shown in Figure 1.
- Figure 3 shows a nucleotide sequence (SEQ ID NO:6) of a native sequence PR0539 cDNA, wherein
- SEQ ID NO:6 is a clone designated herein as "DNA47465-1561 ".
- Figure 4 shows the amino acid sequence (SEQ ID NO:7) derived from the coding sequence of SEQ ID NO:6 shown in Figure 3.
- Figure 5 shows a nucleotide sequence (SEQ ID NO:8) of a native sequence PR0982 cDNA, wherein SEQ ID NO:8 is a clone designated herein as "DNA57700-1408" .
- Figure 6 shows the amino acid sequence (SEQ ID NO:9) derived from the coding sequence of SEQ ID NO: 8 shown in Figure 5.
- Figure 7 shows a nucleotide sequence (SEQ ID NO: 12) of a native sequence PRO 1434 cDNA, wherein SEQ ID NO: 12 is a clone designated herein as "DNA68818-2536" .
- Figure 8 shows the amino acid sequence (SEQ ID NO: 13) derived from the coding sequence of SEQ
- Figure 9 shows a nucleotide sequence (SEQ ID NO: 17) of a native sequence PR01863 cDNA, wherein SEQ ID NO: 17 is a clone designated herein as "DNA59847-2510".
- Figure 10 shows the amino acid sequence (SEQ ID NO: 18) derived from the coding sequence of SEQ ID NO: 17 shown in Figure 9.
- Figure 11 shows a nucleotide sequence (SEQ ID NO : 19) of a native sequence PRO 1917 cDN A , wherein SEQ ID NO: 19 is a clone designated herein as "DNA76400-2528".
- Figure 12 shows the ammo acid sequence (SEQ ID NO 20) derived from the coding sequence of SEQ ID NO 19 shown in Figure 1 1
- Figure 13 shows a nucleotide sequence (SEQ ID NO 21 ) of a native sequence PRO 1868 cDN A, wherein SEQ ID NO 21 is a clone designated herein as "DNA77624-2515 '
- Figure 14 shows the amino acid sequence (SEQ ID NO 22) derived from the coding sequence of SEQ ID NO 21 shown in Figure 13
- Figure 15 shows a nucleotide sequence (SEQ ID NO 23) of a native sequence PR03434 cDNA, wherein SEQ ID NO 23 is a clone designated herein as "DNA77631-2537"
- Figure 16 shows the amino acid sequence (SEQ ID NO 24) derived from the coding sequence of SEQ ID NO 23 shown in Figure 15
- Figure 17 shows a nucleotide sequence (SEQ ID NO 25) ofa native sequence PRO 1927 cDNA, wherein
- SEQ ID NO 25 is a clone designated herein as "DNA82307-2531"
- Figure 18 shows the amino acid sequence (SEQ ID NO 26) derived from the coding sequence of SEQ ID NO 25 shown in Figure 17
- PRO polypeptide and "PRO” as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (1 e , PRO/number) refers to specific polypeptide sequences as described herein
- PRO/number polypeptide and “PRO/number” wherein the term “number” is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein)
- the PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods
- a “native sequence PRO polypeptide comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means The term "native sequence PRO polypeptide” specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e g.
- the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length ammo acids sequences shown in the accompanying figures Start and stop codons are shown m bold font and underlined in the figures However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 m the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the ammo acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.
- the PRO polypeptide "extracellular domain” or “ECD” refers to a form of the PRO polypeptide which is essentially free of the transmembrane and c ⁇ toplasmic domains
- a PRO polypeptide ECD will have less than 1 % of such transmembrane and/or c> toplasmic domains and preferably, will have less than 0 5 % of such domains
- am transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain
- the exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein
- an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified m the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucle
- PRO polypeptide variant means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein
- Such PRO polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C- termmus of the full-length native amino acid sequence
- a PRO polypeptide variant will have at least about 80% amino acid sequence identity, preferably at least about 81 % ammo acid sequence identity, more preferably at least about 82% ammo acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% ammo acid sequence identity, more
- Percent (%) amino acid sequence identity with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the ammo acid residues m the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megahgn (DNASTAR) software Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc and the source
- the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given ammo acid sequence B is calculated as follows
- NCBI-BLAST2 (Altschul et al , Nucleic Acids Res 25 3389-3402 (1997))
- the NCBI-BLAST2 sequence comparison program may be downloaded from http //www ncbi nlm nih gov
- % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows
- PRO variant polynucleotide or "PRO variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein.
- a PRO variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81 % nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91 % nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence
- PRO variant polynucleotides are at least about 30 nucleotides in length, often at least about 60 nucleotides in length, more often at least about 90 nucleotides in length, more often at least about 120 nucleotides in length, more often at least about 150 nucleotides in length, more often at least about 180 nucleotides in length, more often at least about 210 nucleotides in length, more often at least about 240 nucleotides in length, more often at least about 270 nucleotides in length, more often at least about 300 nucleotides in length, more often at least about 450 nucleotides in length, more often at least about 600 nucleotides in length, more often at least about 900 nucleotides in length, or more.
- Percent (%) nucleic acid sequence identity with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessarv , to achieve the maximum percent sequence identity Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in v arious ways that are withm the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST 2, ALIGN or Megahgn (DNASTAR) software For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN 2 wherein the complete source code for the ALIGN 2 program is provided in Table 1 below The ALIGN 2 sequence comparison computer program was authored by Genentech, Inc and the source code shown in Table 1 below has been filed with user documentation in the U S Copyright Office, Washington D C , 20559,
- the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows
- % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN 2 computer program
- % nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al , Methods in Enzymology 266 460-480 (1996))
- a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide encoding nucleic acid and the comparison nucleic acid molecule
- Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al , Nucleic Acids Res 25 3389-3402 (1997))
- NCBI-BLAST2 sequence comparison program may be downloaded from http //www ncbi nlm nih gov
- the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to,
- PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein
- PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide
- the % value of positives is determined by dividing (a) the number of amino acid residues scoring a positive value between the PRO polypeptide ammo acid sequence of interest having a sequence derived from the native PRO polypeptide sequence and the comparison ammo acid sequence of interest (I e , the amino acid sequence against which the PRO polypeptide sequence is being compared) as determined in the BLOSUM62 matrix of WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest
- % value of positives is calculated as described in the immediately preceding paragraph
- Amino acid residues that score a positive value to an amino acid residue of interest are those that are either identical to the ammo acid residue of interest or are a preferred substitution (as defined in Table 6 below) of the amino acid residue of interest
- % value of positives of a given amino acid sequence A to, with, or against a given ammo acid sequence B is calculated as follows
- Isolated, when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-protemaceous solutes
- the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non reducing or reducing conditions using Coomassie blue or, preferably, silver stain Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of the PRO polypeptide natural environment will not be present Ordinarily, however, isolated polypeptide will be prepared by at least one purification step
- an "isolated" PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide encoding nucleic acid
- An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide- encoding nucleic acid molecule as it exists in natural cells
- an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells
- control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
- control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
- Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
- Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
- a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
- a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
- "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
- antibody is used in the broadest sense and specifically covers, for example, single anti-PRO monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody compositions with polyepitopic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO antibodies (see below).
- monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
- “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al. , Current Protocols in Molecular Biology. Wiley Interscience Publishers, (1995).
- “Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1 % sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1 % bovine serum albumin/0.1 %Ficoll/0.1 % polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ml), 0.1 % SDS
- Moderately stringent conditions ma ⁇ be identified as described by Sambrook et al , Molecular Cloning A Laboratory Manual. New York Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e g , temperature, ionic strength and %SDS) less stringent that those described above
- An example of moderately stringent conditions is overnight incubation at 37 °C in a solution comprising 20% formamide, 5 x SSC (150 mM NaCl, 15 mM t ⁇ sodium citrate), 50 mM sodium phosphate (pH 7 6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50 °C
- the skilled artisan will recognize how to adjust the temperature, ionic strength, etc as necerney to accommodate factors such as probe length and the like
- 'epitope tagged when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide "
- the tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused
- the tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes
- Suitable tag polypeptides generally have at least six ammo acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues)
- the term "immunoadhesin” designates antibody-like molecules which combine the binding specificity of a heterologous protein (an adhesin") with the effector functions of immunoglobulin constant domains Structurally, the immunoadhesins comprise a fusion of an ammo acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (l e , is "heterologous"), and an immunoglobulin constant domain sequence
- the adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand
- the immunoglobulin constant domam sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1 , IgG-2, IgG 3, or IgG-4 subtypes, IgA (including IgA-1 and IgA 2), IgE, IgD or IgM "Active” or "
- agonist is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO polypeptide disclosed herein
- agonist is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein
- Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or ammo acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc
- Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide
- Treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder
- Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented
- “Chronic administration” refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time
- “Intermittent” administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature
- “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc
- the mammal is human
- Carriers as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed Often the physiologically acceptable carrier is an aqueous pH buffered solution
- physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids, antioxidants including ascorbic acid, low molecular weight (less than about 10 residues) polypeptide, protems, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, ammo acids such as glycine, glutamine, asparagme, argimne or lysme, monosaccha ⁇ des, disaccha ⁇ des, and other carbohydrates including glucose, mannose, or dextrms, chelating agents such as EDTA, sugar alcohols such as mannitol or
- Papain digestion of antibodies produces two identical antigen-bmding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual "Fc' fragment, a designation reflecting the ability to crystallize readily Pepsin treatment yields an F(ab') ⁇ fragment that has two antigen-combining sites and is still capable of cross linking antigen
- Fv is the minimum antibody fragment which contains a complete antigen recognition and -binding site This region consists of a dimer of one heavy- and one light chain variable domain m tight, non-covalent association It is in this configuration that the three CDRs of each variable domain interact to define an antigen- bmding site on the surface of the V H -V L dimer Collectively, the six CDRs confer antigen-binding specificity to the antibody However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affimtv than the entire binding sue
- the Fab fragment also contains the constant domain of the light chain and the first constant domain (CH I) of the heavy chain Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH 1 domain including one or more cysteines from the antibody hinge region Fab' SH is the designation herein for Fab in which the cysteme res ⁇ due(s) of the constant domains bear a free thiol group F(ab'), antibody fragments originally were produced as pairs of Fab fragments which have hinge cysteines between them Other chemical couplings of antibody fragments are also known
- the "light chains' of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains
- immunoglobulins can be assigned to different classes There are five major classes of immunoglobulins IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e g , IgGl , IgG2, IgG3, IgG4, IgA, and IgA2 "Single-chain Fv" or "sFv' antibody fragments comprise the V H and V L domains of antibody, wherein these domains are present m a single polypeptide chain
- the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the sFv to form the desired structure for antigen binding
- sFv see Pluckthun m The Pharmacology of Monoclonal Antibodies, vol 113, Rosenburg and Moore eds , Springer- Verlag, New York,
- an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes
- the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or , preferably , silver stain Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present Ordinarily, however, isolated antibody will be prepared by at least one purification step
- label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody
- the label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
- solid phase is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
- solid phases encompassed herein include those formed partially or entirely of glass (e.g. , controlled pore glass), polysaccharides (e.g. , agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
- the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275, 149.
- a “liposome” is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal.
- a drug such as a PRO polypeptide or antibody thereto
- the components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
- a "small molecule” is defined herein to have a molecular weight below about 500 Daltons.
- tilel and t ⁇ le2 are two dna or two protein sequences
- sequences can be in uppei- or lower-case an may contain ambiguity
- Max file length is 65535 (limited by unsigned short x in the jmp struct)
- a sequence with 1/3 or more ot its elements ACGTU is assumed to be DNA
- the program may create a tmp file in /tmp to hold info about traceback.
- OxFFFFFFF 1 ⁇ ⁇ 10, 1 ⁇ 11, 1 ⁇ 12, 1 ⁇ 13, 1 ⁇ 14,
- dumpblockO * numsO -- put out a number line- dumpblockO * puthneO - put out a iine (name, [num] , seq, [num]): dumpblockO
- static nm, /* matches in core — for checking */ static lmax, /* lengths of stripped file names */ static ⁇ j[2], /* jmp index for a path */ static nc[2]; /* number at start of current line */ static m[2], /* current elem number -- for gapping */ static s ⁇ z[2], static char *ps[2]; /* ptr to current element */ static char *po[2], /* ptr to next output char slot */ static char oouutt[[22]][[IP_LINE], /* output line */ static char star[P ] I], I* set by stars() */
- *ps[ ⁇ ] toupper(*ps[ ⁇ ]), po[ ⁇ ] + + ; ps[ ⁇ ] + + ,
- *py++ *p ⁇ else if ( ⁇ slower(*px))
- *py++ toupper(*px), if ( ⁇ ndex("ATGCU *(p ⁇ -l))) natgc + + ⁇
- endgaps)? -siz • MAXGAP; ⁇ l + + ; ⁇ else if (siz > 0) ⁇ /* gap in first seq */ gapx+ + ; ngapx + siz;
- the present invention provides newly identifiedand isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides
- PRO polypeptides cDNAs encodmg various PRO polypeptides have been identified and isolated, as disclosed further detail in the Examples below
- proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protem, and will not be changed
- the prote encoded by the full length native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO will be referred to as "PRO/number", regardless of their origin or mode of preparation
- various cDNA clones have been deposited with the ATCC The actual nucleotide sequences of those clones can readily be determined by the skilled artisan by sequencing of the deposited clone using routine methods m the art The predicted amino acid sequence can be determined from the nucleotide sequence
- PRO1800 disclosed in the present application is a newly identified Hep27 homolog and possesses activity typical of that protein
- PR0539 discloses a portion of the full-length native sequence PR0539 (shown in Figure 4 and SEQ ID NO 7) has certain amino acid sequence identity with a portion of a kinesin-related protein from Drosophila melanogaster (AF019250_1) Accordingly, it is presently believed that PR0539 disclosed in the present application is a newly identified member of the Hedgehog signaling pathway protein family and possesses activity typical of the Drosophila Costal 2 protein
- DNA57700-1408 sequence encodes a novel secreted factor designated herein as PR0982.
- PR0982 a novel secreted factor
- PRO 1434 disclosed in the present application is a newly identified nei homolog and may possess activity typical of the nei protein family
- the DNA59847-2510 clone was isolated from a human prostate tissue library As far as is known, the DNA59847-2510 sequence encodes a novel factor designated herein as PR01863, using the WU-BLAST2 sequence alignment computer program, no significant sequence identities to any known proteins were revealed
- PR01917 (shown in Figure 14 and SEQ ID NO 20) has certain amino acid sequence identity with an inositol phosphatase designated in the Dayhoff database as " AF012714 1 " Accordingly, it is presently believed that PR01917 disclosed in the present application is a newly identified member of mositol phosphatase family and may possess enzymatic activity typical of mositol phosphatases
- PRO 1868 polypeptide may find use in the therapeutic treatment of inflammatory diseases as described above and colorectal cancer
- the DNA77631-2537 clone was isolated from a human aortic tissue library using a trapping technique that selects for nucleotide sequences encoding secreted proteins As far as is known, the DNA77631-2537 sequence encodes a novel factor designated herein as PR03434, using the WU-BLAST2 sequence alignment computer program, no significant sequence identities to any known proteins were revealed
- PRO 1927 disclosed in the present application is a newly identified member of the glycosyltransferase family of proteins and may possess glycosylation activity B.
- PRO variants can be prepared.
- PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide.
- amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.
- Variations in the native full-length sequence PRO or in various domains of the PRO described herein can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934.
- Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO.
- the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO.
- Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology.
- Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements.
- Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
- PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO polypeptide.
- PRO fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating PRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO polypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.
- PCR polymerase chain reaction
- Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
- Naturally occurring residues are divided into groups based on common side-chain properties:
- hydrophobic norleucine, met, ala, val, leu, ile
- neutral hydrophilic cys, ser, thr
- Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
- the variations can be made using methods known in the art such as oligonucleotide-mediated (site- directed) mutagenesis, alanine scanning, and PCR mutagenesis.
- Site-directed mutagenesis [Carter et al. , Nucl. Acids Res., .13:4331 (1986); Zoller et al. , Nucl. Acids Res.. 10:6487 (1987)]
- cassette mutagenesis [Wells et al., Gene. 34:315 (1985)]
- restriction selection mutagenesis [Wells et al. , Philos. Trans. R. Soc. London Ser A, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA
- Scanning ammo acid analysis can also be employed to identify one or more ammo acids along a contiguous sequence
- preferred scanning amino acids are relatively small, neutral amino acids
- amino acids include alanine, glycine, se ⁇ ne, and cysteme
- Alanme is typically a preferred scanning amino acid among this group because it eliminates the side chain beyond the beta-carbon and is less likely to alter the main chain conformation of the variant [Cunningham and Wells, Science, 244 1081-1085 (1989)]
- Alanine is also typically preferred because it is the most common ammo acid Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W H Freeman & Co , N Y ), Chothia, J Mol Biol , 150 1 (1976)] If alanine substitution does not yield adequate amounts of variant, an lsote ⁇ c amino acid can be used
- Covalent modifications of PRO are included within the scope of this invention
- One type of covalent modification includes reacting targeted ammo acid residues of a PRO polypeptide with an organic de ⁇ vatizing agent that is capable of reacting with selected side chains or the N- or C terminal residues of the PRO De ⁇ vatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa
- Commonly used crosslinking agents include, e g , l , l-b ⁇ s(d ⁇ azoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-az ⁇ dosal ⁇ cyl ⁇ c acid, homobifunctional lmidoesters, including disuccimmidyl esters such as 3,3'-d ⁇ th ⁇ ob ⁇ s(succm ⁇ m ⁇ dylprop ⁇ onate), bifunctional male
- Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the ammo acid sequence
- the alteration may be made, for example, by the addition of, or substitution by, one or more serine or threomne residues to the native sequence PRO (for O-linked glycosylation sites)
- the PRO ammo acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encodmg the PRO polypeptide at preselected bases such that codons are generated that will translate mto the desired amino acids
- Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide Such methods are described in the art, e g , m WO 87/05330 published 1 1 September 1987 and m Aplin and W ⁇ ston, CRC C ⁇ t Rev Biochem . pp 259 306 (1981)
- Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation
- Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al , Arch Biochem B ⁇ oph ⁇ s , 259 52 (1987) and by Edge et al , Anal Biochem .
- Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al , Meth Enzymol , 138 350 (1987)
- Another type of covalent modification of PRO comprises linking the PRO polypeptide to one of a variety of nonprotemaceous polymers, e g , polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U S Patent Nos 4,640,835, 4,496,689, 4,301, 144, 4,670,417, 4,791 , 192 or4, 179,337
- the PRO of the present invention may also be modified in a way to form a chimeric molecule comprising PRO fused to another, heterologous polypeptide or amino acid sequence
- a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind
- the epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO
- the presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide
- provision of the epitope tag enables the PRO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag
- Various tag polypeptides and their respective antibodies are well known in the art Examples include poly-histidine (poly his) or poly-histidine-glycine (poly-his-gly) tags, the flu HA tag polypeptide and its antibody 12CA5 [Field et al , Mol
- Tag polypeptides include the Flag-peptide [Hopp et al , BioTechnologv.
- the chimeric molecule may comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin
- an immunoglobulin also referred to as an "immunoadhesin”
- a fusion could be to the Fc region of an IgG molecule
- the Ig fusions preferably mclude the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide m place of at least one variable region within an Ig molecule
- the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CHI, CH2 and CH3 regions of an IgG 1 molecule
- US Patent No 5 ,428 , 130 issued June 27, 1995 See also US Patent No 5 ,428 , 130 issued June 27, 1995.
- PRO sequence or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g. , Stewart et l. , Solid-Phase Peptide Synthesis, W.H. Freeman Co. , San Francisco. CA (1969): Merrifield. J. Am. Chem. Soc , 85:2149-2154 (1963)]. In vitro protein synthesis may be performed using manual techniques or by automation.
- Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions.
- Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO.
- DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples.
- the PRO- encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).
- Probes such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases
- Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in
- the oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized.
- the oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like 32 P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al. , supra. Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.
- Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA. 2 Selection and Transformation of Host Cells
- Host cells are transfected or transformed with expression or cloning vectors described herein for PRO production and cultured m conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences
- the culture conditions such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation
- principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology a Practical Approach, M Butler, ed (IRL Press, 1991) and Sambrook et al , supra
- Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells
- Suitable prokaryotes include but are not limited to eubacte ⁇ a, such as Gram-negative or Gram-positive organisms, for example, Enterobacte ⁇ aceae such as E coh
- E cob strains are publicly available, such as E cob K12 strain MM294 (ATCC 31,446), E cob X1776 (ATCC 31,537), E cob stram W3110 (ATCC 27,325) and K5 772 (ATCC 53,635)
- Other suitable prokaryotic host cells include Enterobacte ⁇ aceae such as Eschertchia, e g , E cob, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimunum, Serratia, e g , Serratia marcesc
- colt W3110 strain 9E4 which has the complete genotype tonA ptr3, E cob W3110 strain 27C7 (ATCC 55,244), which has the complete genotype tonA ptr3 phoA El 5 (argF-lac)169 degP ompT kan r , E cob W3110 strain 37D6, which has the complete genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7
- E cob W31 10 strain 40B4 which is strain 37D6 with a non-kanamycin resistant degP deletion mutation, and an E cob strain having mutant pe ⁇ plasmic protease disclosed in U S Patent No 4,946,783 issued 7 August 1990 Alternatively, //; vitro methods of cloning, e g , PCR or other nucleic acid polymerase reactions, are suitable
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO-encoding vectors Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism Others include Schizosaccharomy cespombe (Beach and Nurse, Nature. 290 140 [1981], EP 139,383 published 2 May 1985), Kluweromyces hosts (U S Patent No 4,943,529, Fleer et al , Bio/Technology, 9 968-975 (1991)) such as, e g , K lactis (MW98-8C, CBS683, CBS4574, Louvencourt et al , J Bacte ⁇ ol .
- Schizosaccharomy cespombe Beach and Nurse, Nature. 290 140 [1981], EP 139,383 published 2 May 1985
- Kluweromyces hosts U S Patent No 4,943,529, Fleer et al , Bio/Technology, 9 968
- K fragibs (ATCC 12,424), K bulgancus (ATCC 16,045), K wickeramu (ATCC 24, 178), K waltu (ATCC 56,500), K drosoph ⁇ arum (ATCC 36,906, Van den Berg et al , Bio/Technology, 8 135 (1990)), K thermotolerans , and K marxianus, yarrowia (EP 402,226), Pichia pastons (EP 183,070, Sreekrishna et al , J Basic Microbiol , 28 265-278 [1988]), Candida, Trichoderma reesia (EP 244,234), Neurospora crassa (Case et al , Proc Natl Acad Sci USA.
- Schwanniomyces such as Schwanniomyces occidentals (EP 394,538 published 31 October 1990), and filamentous fungi such as, e g., Neurospora, Pentcilbum, Tolypocladium (WO 91/00357 published 10 January 1991), and Aspergillus hosts such as A nidulans (Ballance et al , Biochem Biophys Res Commun . 112 284 289 [1983], Tilburn et al , Gene. 26 205-221 [1983], Yelton et al , Proc Natl Acad Sci USA.
- Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula A list of specific species that are exemplary of this class of yeasts may be found in C Anthony, The Biochemistry of Methylotrophs. 269 (1982)
- Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms
- invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells
- useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells More specific examples include monkey kidney CV1 line transformed by SV40 (COS 7, ATCC CRL 1651), human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al , J_ Gen Virol . 36 59 (1977)), Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasm, Proc Natl Acad Sci. USA.
- mice sertoh cells TM4, Mather, Biol Reprod , 23 243-251 (1980)
- human lung cells W138, ATCC CCL 75
- human liver cells Hep G2, HB 8065
- mouse mammary tumor MMT 060562, ATCC CCL51
- the nucleic acid (e g , cDNA or genomic DNA) encoding PRO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression
- a replicable vector for cloning (amplification of the DNA) or for expression
- the vector may, for example, be m the form of a plasmid, cosmid, viral particle, or phage
- the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures
- DNA is inserted into an appropriate restriction endonuclease s ⁇ te(s) using techniques known in the art
- Vector components generally include, but are not limited to one or more of a signal sequence an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence Construction of suitable vectors containing one or more of these components employs standard hgation techniques which are known to the skilled artisan
- the PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide
- the signal sequence may be a component of the vector, or it may be a part of the PRO-encoding DNA that is inserted into the vector
- the signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicilhnase, lpp, or heat-stable enterotoxm II leaders
- the signal sequence may be, e g , the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces ⁇ -factor leaders, the latter described m U S Patent No 5,010, 182), or acid phosphatase leader, the C albicans glucoamylase leader (EP 362,
- Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells Such sequences are well known for a variety of bacteria, yeast, and viruses
- the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors m mammalian cells
- Selection genes will typically contain a selection gene, also termed a selectable marker
- Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxms, e g , ampicillin, neomycm, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e g , the gene encodmg D-alamne racemase for Bacilli
- suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase
- An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al , Proc Natl Acad Sci USA.
- a suitable selection gene for use in yeast is the trpl gene present m the yeast plasmid YRp7 [Stinchcomb et al , Nature, 282.39 (1979), Kingsman et al , Gene, 7 141 (1979), Tschemper et al , Gene, 10 157 (1980)]
- the trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No 44076 or PEP4-1 [Jones, Genetics. 85 12 (1977)]
- Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis
- Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the ⁇ -lactamase and lactose promoter systems [Chang et al., Nature, 275 615 (1978), Goeddel et al , Nature. 281 544 (1979)], alkaline phosphatase, a tryptophan (trp) promoter system [Goeddel, Nucleic Acids Res .
- Promoters for use in bacterial systems also will contain a Shine Dalgarno (S D ) sequence operably linked to the DNA encoding PRO
- suitable promoting sequences for use with yeast hosts include the promoters for 3- phosphoglycerate kinase [Hitzeman et al , J Biol Chem . 255 2073 (1980)] or other glycolytic enzymes [Hess et al , J Adv Enzyme Reg , 7 149 (1968), Holland, Biochemistry, 17 4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexok ⁇ nase,pyruvatedecarboxylase,phosphofructok ⁇ nase, glucose- 6-phosphate isomerase, 3-phos ⁇ hoglycerate mutase, pyruvate kinase, t ⁇ osephosphateisomerase.phosphoglucose isomerase, and glucokinase
- yeast promoters which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionem, glyceraldehyde-3- phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization Suitable vectors and promoters for use m yeast expression are further described in EP 73,657
- PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211 ,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e g , the actm promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems
- promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211 ,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegal
- Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA Such sequences are commonly available from the 5' and, occasionally 3 ' , untranslated regions of eukaryotic or viral DNAs or cDN As These regions contain nucleotide segments transcribed as polyadenylated fragments m the untranslated portion of the mRNA encoding PRO
- Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc Natl Acad Sci USA, 77 5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein
- antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes
- the antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected
- Gene expression may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product
- Antibodies useful for immunohistochemical stammg and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific antibody epitope
- PRO may be recovered from culture medium or from host cell lysates If membrane-bound, it can be released from the membrane using a suitable detergent solution (e g T ⁇ ton-X 100) or by enzymatic cleavage Cells employed m expression of PRO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, somcation, mechanical disruption, or cell lysing agents
- PRO may be desired to purify PRO from recombinant cell proteins or polypeptides
- the following procedures are exemplary of suitable purification procedures by fractionation on an ion-exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica or on a cation-exchange resin such as DEAE, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, gel filtration using, for example, Sephadex G-75, protem A Sepharose columns to remove contaminants such as IgG, and metal chelating columns to bind epitope-tagged forms of the PRO
- Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology. 182 (1990), Scopes, Protein Purification Principles and Practice. Springer- Verlag, New York (1982)
- the purification step(s) selected will depend, for example, on the nature of the production process used and the particular PRO produced
- PRO Nucleotide sequences (or their complement) encoding PRO have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and m the generation of .anti-sense RNA and DNA PRO nucleic acid will also be useful for the preparation of PRO polypeptides by the recombinant techniques described herein
- the full-length native sequence PRO gene, or portions thereof may be used as hybridization probes for a cDNA library to isolate the full-length PRO cDNA or to isolate still other cDNAs (for instance, those encoding naturally occurring variants of PRO or PRO from other species) which have a desired sequence identity to the native PRO sequence disclosed herein
- the length of the probes will be about 20 to about 50 bases
- the hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and mtrons of native sequence PRO
- antisense or sense oligonucleotides comprising a singe-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target PRO mRNA (sense) or PRO DNA (antisense) sequences
- Antisense or sense oligonucleotides comprise a fragment of the coding region of PRO DNA Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides.
- Stein and Cohen Cancer Res 48 2659, 1988
- van der Krol et al BioTechniques 6 958, 1988
- binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means
- the antisense oligonucleotides thus may be used to block expression of PRO proteins
- Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases
- Such oligonucleotides with resistant sugar linkages are stable in vivo (l e , capable of resistmg enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences
- sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lys ⁇ ne) Further still, intercalating agents, such as ellipticme, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence Antisense or sense oligonucleotides ma be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaP0 4 mediated DNA transfection electroporation, or by using gene transfer vectors such as Epstein-Barr virus In a preferred procedure, an antisense or sense oligonucleotide is
- Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described m WO 91/04753
- Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors
- conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell
- a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448
- the sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase
- Antisense or sense RNA or DNA molecules are generally at least about 5 bases in length, about 10 bases in length, about 15 bases m length, about 20 bases m length, about 25 bases in length, about 30 bases in length, about 35 bases in length, about 40 bases in length, about 45 bases in length, about 50 bases m length, about 55 bases in length, about 60 bases m length, about 65 bases in length, about 70 bases in length, about 75 bases in length, about 80 bases in length, about 85 bases in length, about 90 bases in length, about 95 bases in length, about 100 bases in length, or more
- the probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related PRO coding sequences
- Nucleotide sequences encoding a PRO can also be used to construct hybridization probes for mapping the gene which encodes that PRO and for the genetic analysis of individuals with genetic disorders
- the nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as in situ hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries
- the coding sequences for PRO encode a protein which binds to another protein (example, where the PRO is a receptor)
- the PRO can be used in assays to identify the other proteins or molecules involved m the bindmg interaction
- inhibitors of the receptor/hgand binding interaction can be identified Protems involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction
- the receptor PRO can be used to isolate
- Nucleic acids which encode PRO or its modified forms can also be used to generate either transgenic animals or "knock out animals which, in turn, are useful in the development and screemng of therapeutically useful reagents
- a transgenic animal e g , a mouse or rat
- a transgenic animal is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e g , an embryonic stage
- a transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops
- cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding PRO Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U S Patent Nos 4,736,866 and 4,870,009 Typically, particular cells would be targeted for
- Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression
- an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition
- non-human homologues of PRO can be used to construct a PRO "knock out" animal which has a defective or altered gene encoding PRO as a result of homologous recombination between the endogenous gene encoding PRO and altered genomic DNA encoding PRO introduced into an embryonic stem cell of the animal
- cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques
- a portion of the genomic DNA encoding PRO can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration
- several kilobases of unaltered flanking DNA both at the 5' and
- Progeny harboring the homologously recombmed DNA in their germ cells can be identified by standard techniques .and used to breed animals in which all cells of the animal contain the homologously recombmed DNA Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the PRO polypeptide.
- Nucleic acid encoding the PRO polypeptides may also be used in gene therapy.
- genes are introduced into cells in order to achieve in vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene.
- Gene therapy includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA.
- Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes in vivo. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane.
- oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.
- nucleic acids there are a variety of techniques available for introducing nucleic acids into viable cells.
- the techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo in the cells of the intended host.
- Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc.
- the currently preferred in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al. , Trends in Biotechnology 11. 205-210 [1993]).
- the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc.
- an agent that targets the target cells such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc.
- proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life.
- the technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem.
- the PRO polypeptides described herein may also be employed as molecular weight markers for protein electrophoresis purposes and the isolated nucleic acid sequences may be used for recombinantly expressing those markers.
- the nucleic acid molecules encoding the PRO polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each PRO nucleic acid molecule of the present invention can be used as a chromosome marker.
- PRO polypeptides and nucleic acid molecules of the present invention may also be used for tissue typing, wherein the PRO polypeptides of the present invention may be differentially expressed in one tissue as compared to another.
- PRO nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis.
- PRO polypeptides described herein may also be employed as therapeutic agents
- the PRO polypeptides of the present mvention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the PRO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle
- Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington s Pharmaceutical Sciences 16th edition, Osol, A Ed (1980)), in the form of lyophihzed formulations or aqueous solutions
- Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids, antioxidants including ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, such as serum albumin, gelatin or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as gly
- formulations to be used for in v ⁇ o administration must be sterile This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophihzation and reconstitution
- compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle
- the route of administration is in accord with known methods, e g injection or infusion by intravenous, intraperitoneal, mtracerebral, intramuscular, intraocular, mtraarte ⁇ al or intralesional routes, topical administration, or by sustained release systems
- Dosages and desired drug concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned The determination of the appropriate dosage or route of administration is well withm the skill of an ordinary physician Animal experiments provide reliable guidance for the determination of effective doses for human therapy Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J and Chappell, W "The use of interspecies scaling in toxicokmetics" In Toxicokinetics and New Drug Development, Yacobi et al , Eds , Pergamon Press, New York 1989, pp 42-96
- a PRO polypeptide or agonist or antagonist thereof When in vivo administration of a PRO polypeptide or agonist or antagonist thereof is employed, normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 ⁇ g/kg/day to 10 mg/kg/day, depending upon the route of administration Guidance as to particular dosages and methods of delivery is provided in the literature, see, for example, U S Pat Nos 4,657,760, 5,206,344, or 5,225,212 It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery m a manner different from that to another organ or tissue Where sustained-release administration of a PRO polypeptide is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of the PRO polypeptide, microencapsulation of the PRO polypeptide is contemplated Microencapsulation of recombinant proteins for sustained release has been successfulh
- the sustained-release formulations of these protems were developed using poly-lactic-coglycohc acid (PLGA) polymer due to its biocompatibihty and wide range of biodegradable properties
- PLGA poly-lactic-coglycohc acid
- the degradation products of PLGA, lactic and glycohc acids, can be cleared quickly within the human body
- the degradabihty of this polymer can be adjusted from months to years depending on its molecular weight and composition Lewis, "Controlled release of bioactive agents from lactide/glycohde polymer, in M Chasin and R Langer (Eds ), Biodegradable Polymers as Drug Delivery Systems (Marcel Dekker New York, 1990), pp 1-41
- This invention encompasses methods of screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists)
- Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the PRO polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins
- Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates
- the assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art All assays for antagonists are common m that they call for contacting the drug candidate with a PRO polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact
- the interaction is binding and the complex formed can be isolated or detected in the reaction mixture
- the PRO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e g , on a microtiter plate, by covalent or non-covalent attachments
- Non-covalent attachment generally is accomplished bv coating the solid surface with a solution of the PRO polypeptide and drying Alternativel
- an immobilized antibody, e g a monoclonal antibody, specific for the PRO polypeptide to be immobilized can be used to anchor it to a solid surface
- the assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e g , the coated surface containing the anchored component
- the non-reacted components are removed, e g , by washing, and complexes anchored on the solid surface are detected
- the originally non-immobilized component carries a detect
- yeast GAL4 89 5789-5793 (1991)
- Many transcriptional activators such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-bmding domain, the other one functioning as the transcription-activation domain
- the yeast expression system described in the foregoing publications (generally referred to as the two hybrid system") takes advantage of this property, and employs two hybrid proteins, one m which the target protem is fused to the DNA-bmding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain
- the expression of a GALl-t ⁇ cZ reporter gene under control of a GAL4-act ⁇ vated promoter depends on reconstitution of GAL4 activity via protein protein interaction Colonies containing interacting polypeptides are detected with a chromogemc substrate for ⁇ galactosidase
- MATCHMAKERTM complete kit for identifying protein-protein interactions between two specific proteins using the two- hybrid technique is commercially available from Clontech
- a reaction mixture is prepared containing the product of the gene and the intra or extracellular component under conditions and for a time allowing for the interaction and binding of the two products
- a placebo may be added to a third reaction mixture, to serve as positive control
- the binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described hereinabove
- the formation of a complex in the control react ⁇ on(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner
- the PRO polypeptide may be added to a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the PRO polypeptide indicates that the compound is an antagonist to the PRO polypeptide
- antagonists may be detected by combining the PRO polypeptide and a potential antagonist with membrane-bound PRO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay.
- the PRO polypeptide can be labeled, such as by radioactivity, such that the number of PRO polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist
- the gene encodmg the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting Coligan et al , Current Protocols in Immun , 1(2) Chapter 5 (1991)
- expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the PRO polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the PRO polypeptide.
- PRO polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.
- labeled PRO polypeptide can be photoaffinity- linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro- sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.
- mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled PRO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.
- potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with PRO polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments.
- a potential antagonist may be a closely related protein, for example, a mutated form of the PRO polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PRO polypeptide.
- Another potential PRO polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation.
- Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA.
- the 5 ' coding portion of the polynucleotide sequence, which encodes the mature PRO polypeptides herein is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length.
- a DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al. , Nucl. Acids Res. , 6:3073 (1979); Cooney et al., Science. 241: 456 (1988); Dervan et al., Science. 251 : 1360 (1991)), thereby preventing transcription and the production of the PRO polypeptide.
- the antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the PRO polypeptide (antisense - Okano, Neurochem..
- oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988).
- the oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of the PRO polypeptide
- antisense DNA oligodeoxy ⁇ bonucleotidesde ⁇ ved from the translation initiation site, e g , between about -10 and + 10 positions of the target gene nucleotide sequence, are preferred
- Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the PRO polypeptide, thereby blocking the normal biological activity of the PRO polypeptide
- small molecules include, but are not limited to, small peptides or peptide-hke molecules, preferably soluble peptides, and synthetic non peptidyl organic or inorganic compounds
- Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA
- Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques For further details see, e g , Rossi, Current Biology. 4 469-471 (1994), and PCT publication No WO 97/33551
- Nucleic acid molecules in triple -helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides
- the base composition of these oligonucleotides is designed such that it promotes t ⁇ ple-hehx formation via Hoogsteen base pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex
- base pairing rules which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex
- the present invention further provides anti PRO antibodies
- Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies
- the anti-PRO antibodies may comprise polyclonal antibodies Methods of preparing polyclonal antibodies are known to the skilled artisan Polyclonal antibodies can be raised m a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant Typically, the immunizing agent and/or adjuvant will be injected m the mammal by multiple subcutaneous or intraperitoneal injections
- the immunizing agent may include the PRO polypeptide or a fusion protein thereof It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovme thyroglobuhn, and soybean trypsin inhibitor Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycol
- the anti-PRO antibodies may, alternatively, be monoclonal antibodies
- Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature. 256:495 (1975).
- a hybridoma method a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
- the lymphocytes may be immunized in vitro.
- the immunizing agent will typically include the PRO polypeptide or a fusion protein thereof.
- PBLs peripheral blood lymphocytes
- spleen cells or lymph node cells are used if non-human mammalian sources are desired.
- the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103].
- Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin.
- rat or mouse myeloma cell lines are employed.
- the hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
- a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
- the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.
- Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J, Immunol.. 133:3001 (1984); Brodeur et al. , Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc. , New York, (1987) pp. 51-63].
- the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO.
- the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
- RIA radioimmunoassay
- ELISA enzyme-linked immunoabsorbent assay
- the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem.. 107:220 (1980).
- the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra] .
- Suitable culture media for this purpose include, for example, Dulbecco' s Modified Eagle ' s Medium and RPMI- 1640 medium.
- the hybridoma cells may be grown in vivo as ascites in a mammal.
- the monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
- the monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567.
- DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g. , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies) .
- the hybridoma cells of the invention serve as a preferred source of such DNA.
- the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
- the DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al. , supral or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
- non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
- the antibodies may be monovalent antibodies.
- Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain.
- the heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking.
- the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.
- In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.
- the anti-PRO antibodies of the invention may further comprise humanized antibodies or human antibodies.
- Humanized forms of non-human (e.g. , murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
- Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- CDR complementary determining region
- Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
- Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
- the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al.. Nature. 321:522-525 (1986): Riechmannet al.
- a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non- human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al. , Nature, 332:323-327 (1988); Verhoeyen et al.
- humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
- humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol. , 227:381 (1991); Marks et al., J. Mol. Biol.. 222:581 (1991)].
- the techniques of Cole et al. and Boemer et al. are also available for the preparation of human monoclonal antibodies (Cole et al. , Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, p. 77 (1985) and Boerner et al. , J. Immunol.. 147(l):86-95 (1991)] .
- human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire.
- transgenic animals e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated.
- human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire.
- This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625, 126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10. 779-783 (1992): Lonberg etal..
- Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens.
- one of the binding specificities is for the PRO
- the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.
- Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature. 305:537-539 (1983)] .
- the first heavy-chain constant region (CH I) containing the site necessary for light-chain binding present in at least one of the fusions.
- DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
- the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
- the preferred interface comprises at least a part of the CH3 region of an antibody constant domain.
- one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan).
- Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
- Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared can be prepared using chemical linkage. Brennan etal. , Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab'), fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
- TAB thionitrobenzoate
- One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
- the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
- Fab' fragments may be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al. , J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab') 2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.
- bispecific antibodies have been produced using leucine zippers.
- the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
- the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
- the fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
- V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
- sFv single-chain Fv
- Antibodies with more than two valencies are contemplated.
- trispecific antibodies can be prepared. Tutt et al. , J. Immunol. 147:60 (1991).
- bispecific antibodies may bind to two different epitopes on a given PRO polypeptide herein.
- an anti-PRO polypeptide arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc ⁇ R), such as Fc ⁇ RI (CD64), Fc ⁇ RII (CD32) and Fc ⁇ RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular PRO polypeptide.
- Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular PRO polypeptide.
- These antibodies possess a PRO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA.
- a cytotoxic agent or a radionuclide chelator such as EOTUBE, DPTA, DOTA, or TETA.
- Another bispecific antibody of interest binds the PRO polypeptide and further binds tissue factor (TF).
- Heteroconjugate antibodies are also within the scope of the present invention.
- Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089].
- the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
- immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.
- effector Function Engineering It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g. , the effectiveness of the antibody in treating cancer.
- cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
- the homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al. , Exp Med. , 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992).
- Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research. 53: 2560-2565 (1993).
- an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities See Stevenson et al , Anti Cancer Drug Design, 3 219 230 ( 1989)
- the invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e g , an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (; e , a radioconjugate)
- a cytotoxic agent such as a chemotherapeutic agent, toxin (e g , an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (; e , a radioconjugate)
- Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ⁇ cm A chain, ab ⁇ n A chain, modeccin A chain, alpha-sarcin, Aleuntes fordii proteins, dianthin proteins, Phytolaca americana protems (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaona ⁇ a officinalis inhibitor, gelonm, mitogelhn, rest ⁇ ctocin, phenomycin, enomycin, and the t ⁇ cothecenes
- radionuchdes are available for the production of radioconjugated antibodies Examples include ,p B ⁇ , 131 I, 131 In, W Y, and
- the antibody may be conjugated to a "receptor ' (such streptavidm) for utilization in tumor pretargetmg wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand” (e g , avidin) that is conjugated to a cytotoxic agent (e g , a radionucleotide)
- a "ligand” e g , avidin
- cytotoxic agent e g , a radionucleotide
- the antibodies disclosed herein may also be formulated as immunoliposomes Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al , Proc Natl Acad Sci USA. 82 3688 (1985), Hwang et al , Proc Natl Acad Sci USA. 77 4030 (1980), and U S Pat Nos 4,485,045 and 4,544,545 Liposomes with enhanced circulation time are disclosed m U S Patent No 5,013,556
- Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylchohne, cholesterol, and PEG-de ⁇ vat ⁇ zedphosphat ⁇ dylethanolam ⁇ ne(PEG- PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al .
- chemotherapeutic agent such as Doxorubicm
- a chemotherapeutic agent is optionally contained withm the liposome See Gabizon et al , J National Cancer Inst , 81(19) 1484 (1989)
- compositions of Antibodies specifically binding a PRO polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be admmistered for the treatment of various disorders in the form of pharmaceutical compositions
- the PRO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred However, hpofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred For example, based upon the variable- region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence Such peptides can be synthesized chemically and/or produced by recombinant DNA technology See, e s .
- the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other
- the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent
- Such molecules are suitably present m combination in amounts that are effective for the purpose intended
- the active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydro xymethylcellulose or gelatin microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano particles, and nanocapsules) or in macroemulsions Such techniques are disclosed in Remington's
- sustained-release preparations may be prepared Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e g , films, or microcapsules
- sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(v ⁇ nylalcohol)), polylactides (U.S. Pat. No.
- anti-PRO antibodies of the invention have various utilities
- anti-PRO antibodies may be used in diagnostic assays for PRO, e g , detecting its expression in specific cells, tissues, or serum
- diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases fZola, Monoclonal Antibodies A Manual of Techniques. CRC Press.
- the antibodies used in the diagnostic assays can be labeled with a detectable moiety
- the detectable moiety should be capable of producing, either directly or indirectly, a detectable signal
- the detectable moiety may be a radioisotope, such as 3 H, 1 C, 3, P, 35 S, or 12 T, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamme, or lucife ⁇ n, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase Any method known m the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al , Nature.
- Anti-PRO antibodies also are useful for the affinity purification of PRO from recombinant cell culture or natural sources
- the antibodies against PRO are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art
- the immobilized antibody then is contacted with a sample containing the PRO to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO, which is bound to the immobilized antibody Finally, the support is washed with another suitable solvent that will release the PRO from the antibody
- EXAMPLES Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA. EXAMPLE 1 Extracellular Domain Homolog ⁇ Screening to Identify Novel Polypeptides and cDNA Encoding Therefor
- the extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss Prot public database were used to search EST databases
- the EST databases included public databases (e g , Dayhoff, GenBank), and proprietary databases (e g LIFESEQTM, Incyte Pharmaceuticals, Palo Alto, CA)
- the search was performed using the computer program BLAST or BLAST-2 (Altschul et al , Methods m Enzymology 266 460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences Those comparisons with a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program ' phrap" (Phil Green, University of Washington, Seattle, WA) Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences using phrap In addition
- oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO polypeptide
- Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100- 1000 bp in length
- the probe sequences are typically 40-55 bp m length
- additional oligonucleotides are synthesized when the consensus sequence is greater than about 1-1 5kbp
- DNA from the libraries was screened by PCR amplification, as per Ausubel et al , Current Protocols in Molecular Biology, with the PCR primer pair A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs
- the cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA
- the cDNA was primed with oligo dT containing a Notl site, linked with blunt to Sail hemikinased adaptors, cleaved with Notl, sized appropriately by gel electrophoresis, and cloned in a defined orientation mto a suitable cloning vector (such as pRKB or pRKD, pRK5B is a precursor of pRK5D that does not contain the Sfil site, see, Holmes et al , Science. 253- 1278-1280 (1991)) in the unique Xhol and Notl sites
- EXAMPLE 2 Isolation of cDNA clones by Amylase Screening 1
- Preparation of oligo dT primed cDNA library mRNA was isolated from a human tissue of interest using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2) This RNA was used to generate an oligo dT primed cDNA library m the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System)
- the double stranded cDNA was sized to greater than 1000 bp and the Sall/Notl linkered cDNA was cloned into Xhol/Notl cleaved vector pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an Sfil restriction enzyme site preceding the Xhol/Notl cDNA cloning sites 2
- a secondary cDNA library was generated in order to preferentially represent the 5 ' ends of the primary cDNA clones
- Sp6 RNA was generated from the primary library (described above), and this RNA was used to generate a random primed cDNA library in the vector pSST-AMY 0 using reagents and protocols from Life Technologies (Super Script Plasmid System, referenced above)
- the double stranded cDNA was sized to 500-1000 bp, linkered with blunt to Notl adaptors, cleaved with Sfil, and cloned into Sfil/Notl cleaved vector pSST-AMY 0 is a cloning vector that has a yeast alcohol dehydrogenase promoter preceding the cDNA cloning sites and the mouse amylase sequence (the mature sequence without the secretion signal) followed by the yeast alcohol dehydrogenase terminator, after the cloning sites
- DNA from the library described in paragraph 2 above was chilled on ice to which was added electrocompetent DH10B bacteria (Life Technologies, 20 ml). The bacteria and vector mixture was then electroporated as recommended by the manufacturer. Subsequently, SOC media (Life Technologies, 1 ml) was added and the mixture was incubated at 37 °C for 30 minutes The transformants were then plated onto 20 standard 150 mm LB plates containing ampicillin and incubated for 16 hours (37°C) Positive colonies were scraped off the plates and the DNA was isolated from the bacterial pellet using standard protocols, e.g. CsCl- gradient The purified DNA was then carried on to the yeast protocols below.
- the yeast methods were divided into three categories (1) Transformation of yeast with the plasmid/cDNA combined vector, (2) Detection and isolation of yeast clones secreting amylase, and (3) PCR amplification of the insert directly from the yeast colony and purification of the DNA for sequencing and further analysis.
- yeast strain used was HD56-5A (ATCC-90785) This strain has the following genotype: MAT alpha, ura3-52, leu2-3, leu2-112, h ⁇ s3-l l, h ⁇ s3-15, MAL + , SUC + , GAL +
- yeast mutants can be employed that have deficient post-translational pathways.
- Such mutants may have translocation deficient alleles in seel I, sec!2, sec62, with truncated secll being most preferred
- antagonists including antisense nucleotides and/or ligands which interfere with the normal operation of these genes, other protems implicated in this post translation pathway (e.g , SEC61p, SEC72p, SEC62p, SEC63p, TDJlp or SSAlp-4p) or the complex formation of these protems may also be preferably employed in combination with the amylase- expressing yeast.
- the cells were then harvested and prepared for transformation by transfer into GS3 rotor bottles in a Sorval GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then resuspended into sterile water, and centrifuged again in 50 ml falcon tubes at 3,500 rpm in a Beckman GS-6KR centrifuge. The supernatant was discarded and the cells were subsequently washed with LiAc/TE (10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM Li 2 OOCCH 3 ), and resuspended into LiAc/TE (2.5 ml).
- LiAc/TE 10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM Li 2 OOCCH 3
- Transformation took place by mixing the prepared cells (100 ⁇ l) with freshly denatured single stranded salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA (1 ⁇ g, vol. ⁇ 10 ⁇ l) in microfuge tubes. The mixture was mixed briefly by vortexing, then 40% PEG/TE (600 ⁇ l, 40% polyethylene glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li 2 OOCCH 3 , pH 7.5) was added. This mixture was gently mixed and incubated at 30 °C while agitating for 30 minutes.
- PEG/TE 600 ⁇ l, 40% polyethylene glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li 2 OOCCH 3 , pH 7.5
- the cells were then heat shocked at 42 °C for 15 minutes, and the reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds, decanted and resuspended into TE (500 ⁇ l, 10 mM Tris-HCl, 1 mM EDTA pH 7.5) followed by recentrifugation. The cells were then diluted into TE (1 ml) and aliquots (200 ⁇ l) were spread onto the selective media previously prepared in 150 mm growth plates (VWR).
- TE 500 ⁇ l, 10 mM Tris-HCl, 1 mM EDTA pH 7.5
- the transformation was performed using a single , large scale reaction, wherein reagent amounts were scaled up accordingly.
- the selective media used was a synthetic complete dextrose agar lacking uracil (SCD-Ura) prepared as described in Kaiser et al. , Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 208-210 (1994). Transformants were grown at 30°C for 2-3 days.
- the detection of colonies secreting amylase was performed by including red starch in the selective growth media.
- Starch was coupled to the red dye (Reactive Red- 120, Sigma) as per the procedure described by
- the positive colonies were picked and streaked across fresh selective media (onto 150 mm plates) in order to obtain well isolated and identifiable single colonies.
- Well isolated single colonies positive for amylase secretion were detected by direct incorporation of red starch into buffered SCD-Ura agar. Positive colonies were determined by their ability to break down starch resulting in a clear halo around the positive colony visualized directly.
- PCR was then performed as follows a Denature 92°C, 5 minutes
- the first 18 nucleotides of the 5 end of these oligonucleotides contained annealing sites for the sequencing primers
- the total product of the PCR reaction from an empty vector was 343 bp
- signal sequence-fused cDNA resulted in considerably longer nucleotide sequences
- DNA30934 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA30934. Based on the DNA30934 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO 1800.
- PCR primers forward and reverse were synthesized: forward PCR primer (30934. fl) 5'-GCATAATGGATGTCACTGAGG-3' (SEQ ID NO:3) reverse PCR primer (30934.rl) 5'-AGAACAATCCTGCTGAAAGCTAG-3' (SEQ ID NO:4) Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30934 sequence which had the following nucleotide sequence hybridization probe (30934.pl) 5'-GAAACGAGGAGGCGGCTCAGTGGTGATCGTGTCTTCCATAGCAGCC-3' (SEQ ID NO:5)
- RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO 1800 (designated herein as DNA35672-2508 [ Figure 1 , SEQ ID NO: l]; and the derived protein sequence for PRO1800.
- DNA41882 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1. This consensus sequence is herein designated DNA41882. Based on the DNA41882 consensus sequence shown, oligonucleotides were synthesized 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0539 RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue DNA sequencing of the clones isolated as described abo ⁇ e gave the full length DNA sequence for PR0539 (designated herein as DNA47465-1561 [ Figure 3, SEQ ID NO 61, and the derived protein sequence for PR0539 The entire nucleotide sequence of DNA47465 1561 is shown m Figure 3 (SEQ ID NO 6) Clone
- DNA47465-1561 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 186-188 and ending at the stop codon at nucleotide positions 2676-2678 (Figure 3)
- the predicted polypeptide precursor is 830 amino acids long ( Figure 4)
- the full length PR0539 protein shown in Figure 4 has an estimated molecular weight of about 95,029 daltons and a pi of about 8 26
- Analysis of the full-length PR0539 sequence shown in Figure 4 evidences the presence of the following leucine zipper pattern sequences from about amino acid 557 to about amino acid 578 and from about amino acid 794 to about ammo acid 815, potential N glycosylation sites from about ammo acid 133 to about ammo acid 136 and from about amino acid 383 to about amino acid 386 and a kinesin-related protein K ⁇ f-4 coiled coil domain from about amino acid 231 to about amino acid 672 Clone DNA47465 1561 has been deposited with ATCC on February 9, 1999
- Incyte EST cluster sequence no 43715 This EST sequence was compared to a variety of EST databases which included public EST databases (e g , GenBank) and a proprietary EST DNA database (LIFESEQTM, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies
- the full length clone shown in Figure 5 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 26-28 and ending at the stop codon found at nucleotide positions 401-403 (SEQ ID NO 8)
- the predicted polypeptide precursor is 125 ammo acids long, has a calculated molecular weight of approximately 14, 198 daltons and an estimated pi of approximately 9 01
- Analysis of the full length PR0982 sequence shown m Figure 6 (SEQ ID NO 9) evidences the presence of a signal peptide from about amino acid 1 to about ammo acid 21 and potential anaphylatoxm domain from about ammo acid 50 to about amino acid 59
- An analysis of the Davhoff database (version 35 45 SwissProt 35) evidenced homology between the PR0982 ammo acid sequence and the following Dayhoff sequences RNTMDCV_1 , A48151 , WAP RAT, S24596, A53640, MT4_HUMAN, U93486 1 , SYNB
- DNA54187 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described m Example 1 above This consensus sequence is herein designated DNA54187 Based on the DNA54187 consensus sequence, oligonucleotides were synthesized 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full length coding sequence for
- PCR primers (forward and reverse) were synthesized forward PCR primer 5'-GAGGTGTCGCTGTGAAGCCAACGG 3' (SEQ ID NO 12) reverse PCR primer 5' CGCTCGATTCTCCATGTGCCTTCC-3 (SEQ ID NO 13)
- oligonucleotide hybridization probe was constructed from the consensus DNA54187 sequence which had the following nucleotide sequence hybridization probe
- RNA for construction of the cDNA libraries was isolated from human retina tissue (LIB94) DNA sequencing of the clones isolated as described above gave the full length DNA sequence for PRO 1434
- PRO 1434 sequence shown in Figure 8 (SEQ ID NO 11 ) evidences the presence of a variety of important protem domains as shown m Figure 8 Clone DNA68818-2536 has been deposited with ATCC on February 9, 1999 and is assigned ATCC deposit no 203657
- Incyte EST cluster sequence no 82468 This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e g , GenBank) and a proprietary EST DNA database (Lifeseq ® , Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies
- EST expressed sequence tag
- the consensus sequence obtained therefrom is herein designated DNA56029 In light of the sequence homology between the DNA56029 sequence and an EST sequence contained
- Clone DNA59847-2510 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 17-19 and ending at the stop codon at nucleotide positions 1328-1330 ( Figure 9)
- the predicted polypeptide precursor is 437 amino acids long ( Figure 10)
- the full-length PRO 1863 protein shown in Figure 10 has an estimated molecular weight of about 46,363 daltons and a pi of about 6 22
- Analysis of the full-length PR01863 sequence shown m Figure 10 evidences the presence of the following a signal peptide from about amino acid 1 to about ammo acid 15, a transmembrane domain from about amino acid 243 to about amino acid 260, potential N-glycosylation sites from about ammo acid 46 to about ammo acid 49, from about amino acid 189 to about amino acid 192 and from about amino acid 382 to about ammo acid 385, glycosaminoglycan attachment sites from about amino acid 51 to about amino acid 54 and from about ammo acid 359
- EST cluster no. 85496 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST cluster sequence from the LIFESEQ ® database, designated EST cluster no. 85496. This EST cluster sequence was then compared to a the EST databases listed above to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al. , Methods in Enzymology 266:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA56415.
- PR01917 has a calculated molecular weight of approximately 55,051 daltons and an estimated pi of approximately 8.14. Additional features include: a signal peptide at about amino acids 1-30; potential N-glycosylation sites at about amino acids 242-245 and 481 -484 , protein kinase C phosphorylation sites at about amino acids 95-97, 182-184, and 427-429; N-myristoylation sites at about amino acids 107-112, 113- 118, 117-122, 118-123, and 128-133; and an endoplasmic reticulum targeting sequence at about amino acids 484-487.
- DNA49803 Based up an observed homology between the DNA49803 consensus sequence and an EST sequence contained withm the Incyte EST clone no 2994689, Incyte EST clone no 2994689 was purchased and its insert obtained and sequenced The sequence of that insert is shown in Figure 13 and is herein designated DNA77624 2515
- Clone DNA77631-2537 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 46-48 and ending at the stop codon at nucleotide positions 3133-3135 (Figure 15)
- the predicted polypeptide precursor is 1029 ammo acids long ( Figure 16)
- the full length PR03434 protem shown in Figure 16 has an estimated molecular w eight of about 114,213 daltons and a pi of about 6 42
- Analysis of the full-length PR03434 sequence shown in Figure 16 evidences the presence of very important polypeptide domains as shown m Figure 16 Clone DNA77631 2537 has been deposited with ATCC on February 9, 1999 and is assigned ATCC deposit no 203651
- EST Cluster No 1913 This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included the databases listed above, including an additional proprietary EST DNA database (Genentech, South San Francisco, CA) to identify existing homologies
- the homology search was performed using the computer program BLAST or BLAST2 (Altshul et al , Methods in Enzymology 266 460-480 (1996)) Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into a consensus DNA sequence with the program "phrap” (Phil Green, University of Washington, Seattle, Washington) The consensus sequence obtained therefrom is herein designated DNA73896
- the full length clone shown in Figure 17 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 51-53 and ending at the stop codon found at nucleotide positions 1695-1697 ( Figure 17, SEQ ID NO 23)
- the predicted polypeptide precursor (Figure 18, SEQ ID NO 24) is 548 amino acids long PRO 1927 has a calculated molecular weight of approximately 63, 198 daltons and an estimated pi of approximately 8 10
- Additional features include a signal peptide at about amino acids 1-23, a putative transmembrane domain at about amino acids 6 25, potential N-glycosylation sites at about ammo acids 5-8, 87-90, 103-106, and 465-469, potential N-my ⁇ stoylation sites at about amino acids 6-11, 136-141 , 370-375, and 509-514.
- EXAMPLE 13 Inhibitory Activity in Mixed Lymphocyte Reaction (MLR) Assay (Assay 67)
- polypeptides of the invention are active as inhibitors of the proliferation of stimulated T-lymphocytes.
- Compounds which inhibit proliferation of lymphocytes are useful therapeutically where suppression of an immune response is beneficial.
- peripheral blood mononuclear cells are isolated from mammalian individuals, for example a human volunteer, by leukopheresis (one donor will supply stimulator PBMCs, the other donor will supply responder PBMCs). If desired, the cells are frozen in fetal bovine serum and DMSO after isolation.
- Frozen cells may be thawed overnight in assay media (37°C, 5% C0 2 ) and then washed and resuspended to 3xl0 6 cells/ml of assay media (RPMI; 10% fetal bovine serum, 1 % penicillin/streptomycin, 1 % glutamine, 1 % HEPES, 1 % non-essential amino acids, 1 % pyruvate).
- assay media 37°C, 5% C0 2
- assay media RPMI; 10% fetal bovine serum, 1 % penicillin/streptomycin, 1 % glutamine, 1 % HEPES, 1 % non-essential amino acids, 1 % pyruvate.
- the stimulator PBMCs are prepared by irradiating the cells (about 3000 Rads).
- the assay is prepared by plating in triplicate wells a mixture of: 100:1 of test sample diluted to 1 % or to 0.1 % ,
- irradiated stimulator cells 50 :1 of irradiated stimulator cells, and 50 :1 of responder PBMC cells.
- 100 microliters of cell culture media or 100 microliter of CD4-IgG is used as the control.
- the wells are then incubated at 37°C, 5% C0 2 for 4 days. On day 5, each well is pulsed with tritiated thymidine (1.0 mC/well; Amersham). After 6 hours the cells are washed 3 times and then the uptake of the label is evaluated.
- PBMCs are isolated from the spleens of Balb/c mice and C57B6 mice.
- the cells are teased from freshly harvested spleens in assay media (RPMI; 10% fetal bovine serum, 1 % penicillin/streptomycin, 1 % glutamine, 1 % HEPES, 1 % non-essential amino acids, 1 % pyruvate) and the PBMCs are isolated by overlaying these cells over Lympholyte M (Organon Teknika), centrifuging at 2000 ⁇ m for 20 minutes, collecting and washing the mononuclear cell layer in assay media and resuspending the cells to lxlO 7 cells/ml of assay media.
- Lympholyte M Organon Teknika
- This assay shows that certain polypeptides of the invention stimulate an immune response and induce inflammation by inducing mononuclear cell, eosinophil and PMN infiltration at the site of injection of the animal Compounds which stimulate an immune response are useful therapeutically where stimulation of an immune response is beneficial
- This skin vascular permeability assay is conducted as follows Hairless guinea pigs weighing 350 grams or more are anesthetized with ketamine (75-80 mg/Kg) and 5 mg/Kg xylazine intramuscularly (IM) A sample of purified polypeptide of the invention or a conditioned media test sample is injected intradermally onto the backs of the test animals with 100 ⁇ l per injection site It is possible to have about 10 30, preferably about 16-24, injection sites per animal One ⁇ l of Evans blue dye (1 % m physiologic buffered saline) is injected intracardially Blemishes at the injection sites are then measured (mm diameter) at 1 hr and 6 hr post
- This assay shows that certain polypeptides of the invention act as potent mitogens for inner ear supporting cells which are auditory hair cell progenitors and, therefore, are useful for inducing the regeneration of auditory hair cells and treating hearing loss m mammals
- the assay is performed as follows Rat UEC-4 ut ⁇ cular epithelial cells are ahquoted into 96 well plates with a density of 3000 cells/well in 200 ⁇ l of serum- containmg medium at 33°C The cells are cultured overnight and are then switched to serum-free medium at 37°C Various dilutions of PRO polypeptides (or nothing for a control) are then added to the cultures and the cells are incubated for 24 hours After the 24 hour incubation, 3 H thymidine (1 ⁇ Ci/well) is added and the cells are then cultured for an additional 24 hours The cultures are then washed to remove umnco ⁇ orated radiolabel, the cells harvested and Cpm per well determined Cpm of at least 30 % or greater in the PRO
- PRO1800 , PR0539-, PR03434- and PR01927-encod ⁇ ng genes are amplified in the genome of certain human lung, colon and/or breast cancers and/or cell lines Amplification is associated with overexpression of the gene product, indicating that the polypeptides are useful targets for therapeutic intervention in certain cancers such as colon, lung, breast and other cancers and diagnostic determination of the presence of those cancers
- Therapeutic agents may take the form of antagonists of PRO1800, PR0539, PR03434 or PR01927 polypeptide, for example, mu ⁇ ne-human chimeric, humanized or human antibodies against a PRO 1800, PR0539, PR03434 or PRO 1927 polypeptide
- the starting material for the screen was genomic DNA isolated from a variety cancers
- the DNA is quantitated precisely, e g , fluoromet ⁇ cally
- DNA was isolated from the cells of ten normal healthy individuals which was pooled and used as assay controls for the gene copy m healthy individuals (not shown)
- the 5' nuclease assay for example, TaqManTM
- real-time quantitative PCR for example, ABI P ⁇ zm 7700 Sequence Detection SystemTM (Perkin Elmer, Applied Biosystems Division, Foster City, CA)
- the results were used to determine whether the DNA encoding PRO 1800, PR0539, PR03434 or PRO 1927 is over-represented m any of the primary lung or colon cancers or cancer cell lines or breast cancer cell lines that were screened
- the primary lung cancers were obtained from individuals with tumors of the type and stage as indicated in Table 6 An explanation of the abbreviations used for the designation of the primary tumors listed m Table 6
- the results of the TaqManTM are reported in delta ( ⁇ ) Ct units.
- One unit corresponds to 1 PCR cycle or approximately a 2-fold amplification relative to normal, two units corresponds to 4-fold, 3 units to 8-fold amplification and so on.
- Quantitation was obtained using primers and a TaqManTM fluorescent probe derived from the PRO1800-, PR0539-, PR03434- or PR01927-encod ⁇ ng gene.
- Regions of PRO1800, PR0539, PR03434 or PRO 1927 which are most likely to contain unique nucleic acid sequences and which are least likely to have spliced out introns are preferred for the primer and probe derivation, e.g , 3 '-untranslated regions
- the sequences for the primers and probes (forward, reverse and probe) used for the PRO1800, PR0539, PR03434 or PRO 1927 gene amplification analysis were as follows PRO 1800 (DNA35672-2508) forward 5'-ACTCGGGATTCCTGCTGTT-3' (SEQ ID NO: 27) probe 5'-AGGCCTTTACCCAAGGCCACAAC-3' (SEQ ID NO:28) reverse 5'-GGCCTGTCCTGTGTTCTCA-3' (SEQ ID N0.29)
- PRQ539 (DNA47465-1561) forward 5'-TCCCACCACTTACTTCCATGAA-3' (SEQ ID NO: 30) probe 5 ' -CTGTGGT ACCC AATTGCCGCCTTGT-3 ' (SEQ ID NO .31 ) reverse 5'-ATTGTCCTGAGATTCGAGCAAGA-3' (SEQ ID NO:32) PRQ3434 (DNA77631-2537) forward 5'-GTCCAGCAAGCCCTCATT-3' (SEQ ID NO:33) probe 5'-CTTCTGGGCCACAGCCCTGC-3" (SEQ ID NO:34) reverse 5'-CAGTTCAGGTCGTTTCATTCA-3' (SEQ ID NO:35)
- PRO 1927 (DNA82307-2531) forward 5'-CCAGTCAGGCCGTTTTAGA-3' (SEQ ID NO:36) probe 5'-CGGGCGCCCAAGTAAAAGCTC-3' (SEQ ID NO:37) reverse 5 ' -C AT A AAGT AGT ATATGC ATTCC AGTGTT-3 ' (SEQ ID NO : 38)
- the 5' nuclease assay reaction is a fluorescent PCR-based technique which makes use of the 5' exonuclease activity of Taq DNA polymerase enzyme to monitor amplification in real time.
- Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction.
- a third oligonucleotide, or probe is designed to detect nucleotide sequence located between the two PCR primers.
- the probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe.
- the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner.
- the resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore.
- One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative inte ⁇ retation of the data.
- the 5 ' nuclease procedure is run on a real-time quantitative PCR device such as the ABI Prism 7700TM Sequence Detection.
- the system consists of a thermocycler, laser, charge-coupled device (CCD) camera and computer.
- the system amplifies samples in a 96-well format on a thermocycler.
- laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD.
- the system includes software for running the instrument and for analyzing the data.
- Ct 5' Nuclease assay data are initially expressed as Ct, or the threshold cycle. This is defined as the cycle at which the reporter signal accumulates above the background level of fluorescence.
- the ⁇ Ct values are used as quantitative measurement of the relative number of starting copies of a particular target sequence in a nucleic acid sample when comparing cancer DNA results to normal human DNA results.
- Table 6 describes the stage, T stage and N stage of various primary tumors which were used to screen the PRO1800, PR0539, PR03434 and PR01927 compounds of the invention. Table 6 Primary Lung and Colon Tumor Profiles
- DNA was prepared from cultured cell lines, primary tumors, normal human blood. The isolation was performed using purification kit, buffer set and protease and all from Quiagen, according to the manufacturer's instructions and the description below.
- Cell culture lysis :
- Cells were washed and trypsinized at a concentration of 7.5 x 10 8 per tip and pelleted by centrifuging at 1000 ⁇ m for 5 minutes at 4°C, followed by washing again with 1/2 volume of PBS recentrifugation. The pellets were washed a third time, the suspended cells collected and washed 2x with PBS. The cells were then suspended into 10 ml PBS. Buffer Cl was equilibrated at 4°C. Qiagen protease #19155 was diluted into 6.25 ml cold ddH 2 0 to a final concentration of 20 mg/ml and equilibrated at 4°C.
- 10 ml of G2 Buffer was prepared by diluting Qiagen RNAse A stock (100 mg/ml) to a final concentration of 200 ⁇ g/ml. Buffer C l ( 10 ml, 4°C) and ddH20 (40 ml, 4°C) were then added to the 10 ml of cell suspension, mixed by inverting and incubated on ice for 10 minutes. The cell nuclei were pelleted by cent ⁇ fuging m a Beckman swinging bucket rotor at 2500 ⁇ m at 4°C for 15 minutes The supernatant was discarded and the nuclei were suspended with a vortex mto 2 ml Buffer Cl (at 4°C) and 6 ml ddH,0, followed by a second 4°C centrifugation at 2500 ⁇ m for 15 minutes The nuclei were then resuspended mto the residual buffer using 200 ⁇ l per tip G2 buffer (10 ml) was added to the suspended nucle
- Solid human tumor sample preparation and lysis Tumor samples were weighed and placed mto 50 ml conical tubes and held on ice Processing was limited to no more than 250 mg tissue per preparation (1 tip/preparation)
- the protease solution was freshly prepared by diluting mto 6.25 ml cold ddH-,0 to a final concentration of 20 mg/ml and stored at 4°C G2 buffer (20 ml) was prepared by diluting DNAse A to a final concentration of 200 mg/ml (from 100 mg/ml stock)
- the tumor tissue was homogenated in 19 ml G2 buffer for 60 seconds using the large tip of the polytron in a laminar- flow TC hood in order to avoid inhalation of aerosols, and held at room temperature Between samples, the polytron was cleaned by spinning at 2 x 30 seconds each m 2L ddH-,0, followed by G2 buffer (50 ml) If tissue was still present on the generator tip, the apparatus was disassembled and cleaned
- Genomic DNA was equilibrated ( 1 sample per maxi tip preparation) with 10 ml QBT buffer QF elution buffer was equilibrated at 50°C The samples were vortexed for 30 seconds, then loaded onto equilibrated tips and drained by gravity The tips were washed with 2 x 15 ml QC buffer The DNA was eluted into 30 ml silamzed, autoclaved 30 ml Corex tubes with 15 ml QF buffer (50"C) Isopropanol (10 5 ml) was added to each sample, the tubes covered with parafin and mixed by repeated inversion until the DNA precipitated Samples were pelleted by centrifugation in the SS-34 rotor at 15,000 ⁇ m for 10 minutes at 4°C The pellet location was marked, the supernatant discarded, and 10 ml 70% ethanol (4°C) was added Samples were pelleted again by centrifugation on the SS 34 rotor at 10,000 ⁇ m for 10 minutes
- DNA levels in each tube were quantified by standard A 260 , A, 80 spectrophotometry on a 1 20 dilution (5 ⁇ l DNA + 95 ⁇ l ddH,0) using the 0 1 ml quartz cuvetts in the Beckman DU640 spectrophotometer A 260 /A 280 ratios were in the range of 1 8-1 9
- Each DNA samples was then diluted further to approximately 200 ng/ml in TE (pH 8 5) If the original material was highly concentrated (about 700 ng/ ⁇ l), the material was placed at 50°C for several hours until resuspended
- Fluoromet ⁇ c DNA quantitation was then performed on the diluted material (20-600 ng/ml) using the manufacturer's guidelines as modified below This was accomplished by allowing a Hoeffer DyNA Quant 200 fluorometer to warm-up for about 15 minutes
- the Hoechst dye working solution (#H33258, 10 ⁇ l, prepared within 12 hours of use) was diluted into 100 ml 1 x TNE buffer A 2 ml cuvette was filled with the fluorometer solution, placed into the machine, and the machine was zeroed pGEM 3Zf(+) (2 ⁇ l, lot #360851026) was added to 2 ml of fluorometer solution and calibrated at 200 units An additional 2 ⁇ l of pGEM 3Zf(+) DNA was then tested and the reading confirmed at 400 +/ 10 units Each sample was then read at least m triplicate When 3 samples were found to be within 10% of each other, their average was taken and this value was used as the quantification value
- the fluoromet ⁇ cly determined concentration was then used to dilute each sample to 10 ng/ ⁇ l in ddH 2 0 This was done simultaneously on all template samples for a single TaqMan plate assay, and with enough material to run 500-1000 assays
- the samples were tested in triplicate with TaqmanTM primers and probe both B-actin and GAPDH on a single plate with normal human DNA and no-template controls
- the diluted samples were used provided that the CT value of normal human DNA subtracted from test DNA was +/- 1 Ct
- the diluted, lot-qualified genomic DNA was stored m l 0 ml ahquots at -80°C Ahquots which were subsequently to be used in the gene amplification assay were stored at 4°C Each 1 ml aliquot is enough for 8-9 plates or 64 tests Gene amplification assay
- the PRO1800, PR0539, PR03434 and PR01927 compounds of the invention were screened in the following primary tumors and the resulting ⁇
- This assay shows that certain polypeptides of the invention act to induce an increase in the number of pancreatic ⁇ -cell precursor cells and, therefore, are useful for treating various insulin deficient states in mammals, including diabetes mellitus.
- the assay is performed as follows. The assay uses a primary culture of mouse fetal pancreatic cells and the primary readout is an alteration in the expression of markers that represent either ⁇ -cell precursors or mature ⁇ -cells. Marker expression is measured by real time quantitative PCR (RTQ- PCR); wherein the marker being evaluated is a transcription factor called Pdxl .
- RTQ- PCR real time quantitative PCR
- the pancreata are dissected from E14 embryos (CD1 mice). The pancreata are then digested with collagenase/dispase in F12/DMEM at 37°C for 40 to 60 minutes (collagenase/dispase, 1.37 mg/ml, Boehringer Mannheim, #1097113). The digestion is then neutralized with an equal volume of 5 % BSA and the cells are washed once with RPMI1640. At day 1 , the cells are seeded into 12-well tissue culture plates (pre-coated with laminin, 20 ⁇ g/ml in PBS, Boehringer Mannheim, #124317). Cells from pancreata from 1-2 embryos are distributed per well.
- the culture medium for this primary cuture is 14F/1640.
- the media is removed and the attached cells washed with RPMI/ 1640. Two mis of minimal media are added in addition to the protein to be tested.
- the media is removed and RNA prepared from the cells and marker expression analyzed by real time quantitative RT-PCR. A protein is considered to be active in the assay if it increases the expression of the relevant ⁇ -cell marker as compared to untreated controls.
- 14F/1640 is RPMI 1640 (Gibco) plus the following: group A 1: 1000 group B 1 : 1000 recombinant human insulin 10 ⁇ g/ml
- Bovine pituitary extract 60 ⁇ g/ml
- Gentamycin 100 ng/ml Group A (in 10ml PBS) Transferrin, lOOmg (Sigma T2252)
- transferrin 10 ⁇ g/ml
- insulin 1 ⁇ g/ml
- gentamycin 100 ng/ml
- aprotinin 50 ⁇ g/ml
- BPE 15 ⁇ g/ml
- This assay shows that certain polypeptides of the invention act to induce differentiation of pancreatic ⁇ -cell precursor cells into mature pancreatic ⁇ cells and, therefore, are useful for treating various insulin deficient states in mammals, including diabetes melhtus
- the assay is performed as follows The assay uses a primary culture of mouse fetal pancreatic cells and the primary readout is an alteration m the expression of markers that represent either ⁇ -cell precursors or mature ⁇ -cells Marker expression is measured by real time quantitative PCR (RTQ-PCR), wherein the marker being evaluated is insulin
- the pancreata are dissected from E14 embryos (CD1 mice) The pancreata are then digested with collagenase/dispase in F12/DMEM at 37°C for 40 to 60 minutes (collagenase/dispase, 1 37 mg/ml, Boehringer Mannheim, #1097113) The digestion is then neutralized with an equal volume of 5 % BSA and the cells are washed once with RPMI1640 At day 1 , the cells are seeded into 12 well tissue culture plates (pre-coated with laminin, 20 ⁇ g/ml in PBS, Boehringer Mannheim, #124317) Cells from pancreata from 1 2 embryos are distributed per well The culture medium for this primary cuture is 14F/1640 At day 2, the media is removed and the attached cells washed with RPMI/ 1640 Two mis of minimal media are added in addition to the protein to be tested At day 4, the media is removed and RNA prepared from the cells and marker expression analyzed by real time quantitative RT-PCR A
- Epidermal Growth Factor lOO ⁇ g (BRL 100004) Trnodothyronme,10 ⁇ l of 5x10 6 M (Sigma T5516) Ethanolamine, lOO ⁇ l of 10 ' M (Sigma E0135) Phosphoethalamine, lOO ⁇ l of 10 ' M (Sigma P0503) Selenium, 4 ⁇ l of 10 ' M (Aesar #12574)
- Hydrocortisone 2 ⁇ l of 5X10 3 M (Sigma #H0135)
- Progesterone lOO ⁇ l of 1 10 3 M (Sigma #P6149)
- This assay shows that certain polypeptides of the invention act to induce proliferation of mammalian kidney mesangial cells and, therefore, are useful for treating kidney disorders associated with decreased mesangial cell function such as Berger disease or other nephropathies associated with Schonlem-Henoch pu ⁇ ura, celiac disease, dermatitis he ⁇ etiformis or Crohn disease
- the assay is performed as follows On day one, mouse kidney mesangial cells are plated on a 96 well plate in growth media (3 1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium, 95 % fetal bovine serum, 5 % supplemented with 14 mM HEPES) and grown overnight On day 2, PRO polypeptides are diluted at 2 concentrat ⁇ ons(l % and 0 1 %) m serum-free medium and added to the cells Control samples are serum free medium alone On day 4, 20 ⁇ l of the Cell Titer 96 Aqueous one solution reagent (Progema)
- EXAMPLE 20 Fibroblast (BHK-21) Proliferation This assay shows that certain pol> peptides of the invention act to induce proliferation of mammalian fibroblast cells in culture and, therefore, function as useful growth factors in mammalian systems
- the assay is performed as follows BHK-21 fibroblast cells plated in standard growth medium at 2500 cells/well m a total volume of 100 ⁇ l
- the PRO polypeptide, ⁇ -FGF (positive control) or nothing (negative control) are then added to the wells in the presence of 1 ⁇ g/ml of hepa ⁇ n for a total final volume of 200 ⁇ l
- the cells are then incubated at 37°C for 6 to 7 days After incubation, the media is removed, the cells are washed with PBS and then an acid phosphatase substrate reaction mixture (100 ⁇ l/well) is added The cells are then incubated at 37°C for 2 hours 10 ⁇ l per well of IN NaOH is then added to stop the acid phosphatas
- This assay shows that certain pol ⁇ peptides of the invention act to induce redifferentiation of chondrocytes, therefore, are expected to be useful for the treatment of various bone and/or cartilage disorders such as, for example, sports injuries and arthritis
- the assay is performed as follows Porcine chondrocytes are isolated by overnight collagenase digestion of articulary cartilage of metaca ⁇ ophalangeal joints of 4 6 month old female pigs The isolated cells are then seeded at 25,000 cells/cm 1 in Ham F-12 containing 10% FBS and 4 ⁇ g/ml gentamycin The culture media is changed every third day and the cells are then seeded in 96 well plates at 5,000 cells/well m lOO ⁇ l of the same media without serum and 100 ⁇ l of the test PRO polypeptide, 5 nM staurosporm (positive control) or medium alone (negative control) is added to give a final volume of 200 ⁇ l/well After 5 days of incubation at 37°C , a picture of each
- EXAMPLE 22 Use of PRO as a hybridization probe The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe
- DNA comprising the coding sequence of full-length or mature PRO as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human tissue cDNA libraries or human tissue genomic libraries
- Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions
- Hybridization of radiolabeled PRO-de ⁇ ved probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0 1 % SDS, 0 1 % sodium pyrophosphate, 50 mM sodium phosphate, pH
- DNAs having a desired sequence identity with the DNA encodmg full-length native sequence PRO can then be identified using standard techniques known in the art
- This example illustrates preparation of an unglycosylated form of PRO by recombinant expression in E cob
- the DNA sequence encoding PRO is initially amplified using selected PCR primers
- the primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector
- a variety of expression vectors may be employed
- An example of a suitable vector is pBR322 (derived from E cob, see Bolivar et al , Gene, 2_95 (1977)) which contains genes for ampicillin and tetracycline resistance
- the vector is digested with restriction enzyme and dephosphorylated
- the PCR amplified sequences are then ligated into the vector
- the vector will preferably include sequences which encode for an antibiotic resistance gene, a t ⁇ promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO coding region, lambda transcriptional terminator, and an argU gene
- the hgation mixture is then used to transform a selected E cob strain using the methods described in Sambrook et al , supra Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing Selected clones can be grown overnight m liquid culture medium such as LB broth supplemented with antibiotics The overnight culture may subsequently be used to inoculate a larger scale culture The cells are then grown to a desired optical density, du ⁇ ng which the expression promoter is turned on
- the cells After culturing the cells for several more hours, the cells can be harvested by centrifugation
- the cell pellet obtained by the centrifugation can be solubihzed using various agents known in the art, and the solubihzed PRO protem can then be purified using a metal chelating column under conditions that allow tight binding of the protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK02016081T DK1300417T3 (da) | 1999-01-12 | 1999-12-01 | Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor |
EP02016080A EP1283215B1 (de) | 1999-02-10 | 1999-12-01 | Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren |
EP02016081A EP1300417B1 (de) | 1999-01-12 | 1999-12-01 | Sekretiertes und transmembranes Polypeptid und dafür kodierende Nukleinsäure |
EP02016082A EP1251173B1 (de) | 1998-12-16 | 1999-12-01 | Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren |
DK02016082T DK1251173T3 (da) | 1998-12-16 | 1999-12-01 | Secernerede og transmembrane polypeptider og nucleinsyrer kodende for disse |
EP02016083A EP1277833B1 (de) | 1999-02-12 | 1999-12-01 | Gen das in Tumoren amplifiziert ist und damit zusammenhängende Materiale und Verfahren |
DK02016083T DK1277833T3 (da) | 1999-02-12 | 1999-12-01 | Gener, der opformeres i tumorer, samt relaterede materialer og metoder |
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11285198P | 1998-12-16 | 1998-12-16 | |
US11314598P | 1998-12-16 | 1998-12-16 | |
US113145P | 1998-12-16 | ||
US112851P | 1998-12-16 | ||
US11351198P | 1998-12-22 | 1998-12-22 | |
US113511P | 1998-12-22 | ||
US11555899P | 1999-01-12 | 1999-01-12 | |
US11573399P | 1999-01-12 | 1999-01-12 | |
US11556599P | 1999-01-12 | 1999-01-12 | |
US115733P | 1999-01-12 | ||
US115558P | 1999-01-12 | ||
US115565P | 1999-01-12 | ||
US11934199P | 1999-02-09 | 1999-02-09 | |
US119341P | 1999-02-09 | ||
US11953799P | 1999-02-10 | 1999-02-10 | |
US119537P | 1999-02-10 | ||
US11996599P | 1999-02-12 | 1999-02-12 | |
US119965P | 1999-02-12 | ||
PCT/US1999/012252 WO1999063088A2 (en) | 1998-06-02 | 1999-06-02 | Membrane-bound proteins and nucleic acids encoding the same |
WOPCT/US99/12252 | 1999-06-02 | ||
PCT/US1999/028634 WO2000036102A2 (en) | 1998-12-16 | 1999-12-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02016081A Division EP1300417B1 (de) | 1999-01-12 | 1999-12-01 | Sekretiertes und transmembranes Polypeptid und dafür kodierende Nukleinsäure |
EP02016080A Division EP1283215B1 (de) | 1999-02-10 | 1999-12-01 | Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren |
EP02016082A Division EP1251173B1 (de) | 1998-12-16 | 1999-12-01 | Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren |
EP02016083A Division EP1277833B1 (de) | 1999-02-12 | 1999-12-01 | Gen das in Tumoren amplifiziert ist und damit zusammenhängende Materiale und Verfahren |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1141285A2 true EP1141285A2 (de) | 2001-10-10 |
Family
ID=27578476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99962992A Withdrawn EP1141285A2 (de) | 1998-12-16 | 1999-12-01 | Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1141285A2 (de) |
JP (5) | JP2003521229A (de) |
KR (2) | KR100468977B1 (de) |
AU (7) | AU777006B2 (de) |
CA (1) | CA2348757A1 (de) |
IL (11) | IL142794A0 (de) |
MX (1) | MXPA01006057A (de) |
WO (1) | WO2000036102A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1163337B1 (de) * | 1999-03-11 | 2011-03-02 | Merck Serono SA | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US6914130B2 (en) * | 1998-06-17 | 2005-07-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2008201101B2 (en) * | 1999-03-11 | 2011-01-20 | Merck Serono Sa | Vascular adhesion molecules and modulation of their function |
KR100543857B1 (ko) * | 1999-09-01 | 2006-01-23 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 |
DE19947010A1 (de) * | 1999-09-30 | 2001-04-05 | Universitaetsklinikum Freiburg | Das Gen PRV-1 und dessen Verwendung |
WO2001083719A2 (en) * | 2000-04-28 | 2001-11-08 | Millennium Pharmaceuticals, Inc. | 25692, a novel human o-methyltransferase family member and uses thereof |
GB0110273D0 (en) * | 2001-04-26 | 2001-06-20 | Inpharmatica Ltd | Novel proteins |
NZ533736A (en) * | 2001-12-19 | 2006-09-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor and inhibiting cell growth |
EP1514942A4 (de) * | 2002-05-17 | 2007-05-16 | Kyowa Hakko Kogyo Kk | Verfahren zur suche nach einer substanz mit antidiabetischer wirkung |
JP2006501290A (ja) * | 2002-10-02 | 2006-01-12 | デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング | エネルギー恒常性の調節に関与するMipp1相同性を有する核酸およびタンパク質 |
NZ594285A (en) | 2005-11-04 | 2013-02-22 | Genentech Inc | USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES |
JP2010504955A (ja) | 2006-09-28 | 2010-02-18 | メルク セローノ ソシエテ アノニム | 接合部接着分子c(jam−c)結合化合物とその利用方法 |
CA2667997C (en) | 2006-11-02 | 2016-10-11 | Genentech, Inc. | Humanized anti-factor d antibodies and uses thereof |
AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
EP3141560A3 (de) | 2008-05-06 | 2017-05-24 | Genentech, Inc. | Affinitätsgereifte crig-varianten |
CA2920666A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
SG11201608868PA (en) | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
EP3368090A1 (de) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831058A (en) * | 1996-03-19 | 1998-11-03 | Otsuka Pharmaceutical Co., Ltd. | Human GDP dissociation stimulating protein gene |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014331A1 (en) * | 1994-11-07 | 1996-05-17 | Merck & Co., Inc. | Modified neuropeptide y receptors |
AU1532697A (en) * | 1996-01-12 | 1997-08-01 | Genetics Institute Inc. | Beta-chemokine, h1305 (mcp-2) |
JP2001515361A (ja) * | 1997-05-06 | 2001-09-18 | ザイモジェネティクス,インコーポレイティド | 新規な腫瘍抗原 |
DE19818620A1 (de) * | 1998-04-21 | 1999-10-28 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Blase-Normal |
JP2002519030A (ja) * | 1998-06-26 | 2002-07-02 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒトシグナルペプチド含有タンパク質 |
WO2000004135A2 (en) * | 1998-07-16 | 2000-01-27 | Incyte Pharmaceuticals, Inc. | Human scad-related molecules, scrm-1 and scrm-2 |
DE19849044A1 (de) * | 1998-10-23 | 2000-04-27 | Univ Ludwigs Albert | Das Gen PRV-1 und dessen Verwendung |
JP2002530080A (ja) * | 1998-11-19 | 2002-09-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 免疫グロブリン・スーパーファミリー・タンパク質 |
DK1623989T3 (da) * | 1999-03-08 | 2007-10-15 | Genentech Inc | Sammensætninger og fremgangsmåder til diagnosticering af tumorer |
-
1999
- 1999-12-01 KR KR10-2004-7013508A patent/KR100468977B1/ko not_active IP Right Cessation
- 1999-12-01 IL IL14279499A patent/IL142794A0/xx active IP Right Grant
- 1999-12-01 CA CA002348757A patent/CA2348757A1/en not_active Abandoned
- 1999-12-01 EP EP99962992A patent/EP1141285A2/de not_active Withdrawn
- 1999-12-01 MX MXPA01006057A patent/MXPA01006057A/es active IP Right Grant
- 1999-12-01 WO PCT/US1999/028634 patent/WO2000036102A2/en active Application Filing
- 1999-12-01 AU AU19320/00A patent/AU777006B2/en not_active Expired
- 1999-12-01 KR KR10-2001-7007461A patent/KR100468978B1/ko not_active IP Right Cessation
- 1999-12-01 JP JP2000588351A patent/JP2003521229A/ja not_active Withdrawn
-
2001
- 2001-04-25 IL IL142794A patent/IL142794A/en not_active IP Right Cessation
-
2003
- 2003-08-14 JP JP2003293651A patent/JP2004041218A/ja not_active Withdrawn
- 2003-08-14 JP JP2003293650A patent/JP2004041217A/ja not_active Withdrawn
-
2004
- 2004-12-10 AU AU2004237842A patent/AU2004237842B2/en not_active Expired
- 2004-12-14 AU AU2004237921A patent/AU2004237921B2/en not_active Expired
- 2004-12-14 AU AU2004237920A patent/AU2004237920B2/en not_active Expired
- 2004-12-14 AU AU2004237922A patent/AU2004237922B2/en not_active Expired
- 2004-12-14 AU AU2004237919A patent/AU2004237919B2/en not_active Expired
- 2004-12-14 AU AU2004237923A patent/AU2004237923B2/en not_active Expired
-
2006
- 2006-10-17 JP JP2006282251A patent/JP2007075118A/ja not_active Withdrawn
-
2007
- 2007-06-13 JP JP2007156006A patent/JP2007312779A/ja not_active Withdrawn
-
2008
- 2008-01-03 IL IL188576A patent/IL188576A0/en unknown
- 2008-01-03 IL IL188577A patent/IL188577A0/en unknown
- 2008-01-03 IL IL188581A patent/IL188581A0/en unknown
- 2008-01-03 IL IL188579A patent/IL188579A0/en unknown
- 2008-01-03 IL IL188580A patent/IL188580A0/en unknown
- 2008-01-03 IL IL188578A patent/IL188578A0/en unknown
-
2009
- 2009-09-13 IL IL200883A patent/IL200883A0/en unknown
- 2009-09-17 IL IL201001A patent/IL201001A0/en unknown
- 2009-09-17 IL IL201030A patent/IL201030A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831058A (en) * | 1996-03-19 | 1998-11-03 | Otsuka Pharmaceutical Co., Ltd. | Human GDP dissociation stimulating protein gene |
Non-Patent Citations (4)
Title |
---|
DATABASE EMBL [Online] md78c02.r1 Soares mouse embryo NbME1cDNA clone, 22 June 1996 (1996-06-22) MARRA M ET AL.: "The WashU-HHMI Mouse EST Project" Database accession no. MM96732 XP002232923 * |
KLEIN R D ET AL: "SELECTION FOR GENES ENCODING SECRETED PROTEINS AND RECEPTORS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 93, no. 14, 9 July 1996 (1996-07-09), pages 7108-7113, XP002061411 ISSN: 0027-8424 * |
See also references of WO0036102A2 * |
TASHIRO K ET AL: "SIGNAL SEQUENCE TRAP: A CLONING STRATEGY FOR SECRETED PROTEINS AND TYPE I MEMBRANE PROTEINS" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 261, 1993, pages 600-603, XP002911163 ISSN: 0036-8075 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1163337B1 (de) * | 1999-03-11 | 2011-03-02 | Merck Serono SA | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004237920B2 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
US20090142800A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
EP1341814A2 (de) | Sekretierte- und transmembranpolypeptide sowie dafür kodierende nukleinsäuren | |
AU2474700A (en) | Secreted amd transmembrane polypeptides and nucleic acids encoding the same | |
US7795412B2 (en) | Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells | |
EP1283215B1 (de) | Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren | |
EP1277833B1 (de) | Gen das in Tumoren amplifiziert ist und damit zusammenhängende Materiale und Verfahren | |
CA2406256A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
NZ529541A (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
NZ536887A (en) | PRO 1800 polypeptides and diagonistic methods and treatment of neoplastic diseases | |
EP1251173A2 (de) | Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010511 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100831 |